Renal association clinical practice guideline on haemodialysis by Ashby, D. et al.
This is a repository copy of Renal association clinical practice guideline on haemodialysis.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/153214/
Version: Published Version
Article:
Ashby, D., Borman, N., Burton, J. et al. (22 more authors) (2019) Renal association clinical
practice guideline on haemodialysis. BMC Nephrology, 20. 379. 
https://doi.org/10.1186/s12882-019-1527-3
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
GUIDELINES Open Access
Renal Association Clinical Practice Guideline
on Haemodialysis
Damien Ashby1*, Natalie Borman2, James Burton3, Richard Corbett1, Andrew Davenport4, Ken Farrington5,
Katey Flowers2, James Fotheringham6, R. N. Andrea Fox7, Gail Franklin8, Claire Gardiner9, R. N. Martin Gerrish10,
Sharlene Greenwood11, Daljit Hothi12, Abdul Khares13, Pelagia Koufaki14, Jeremy Levy1, Elizabeth Lindley15,
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Abstract
This guideline is written primarily for doctors and nurses working in dialysis units and related areas of medicine in
the UK, and is an update of a previous version written in 2009. It aims to provide guidance on how to look after
patients and how to run dialysis units, and provides standards which units should in general aim to achieve. We
would not advise patients to interpret the guideline as a rulebook, but perhaps to answer the question: “what does
good quality haemodialysis look like?”
The guideline is split into sections: each begins with a few statements which are graded by strength (1 is a firm
recommendation, 2 is more like a sensible suggestion), and the type of research available to back up the statement,
ranging from A (good quality trials so we are pretty sure this is right) to D (more like the opinion of experts than
known for sure). After the statements there is a short summary explaining why we think this, often including a
discussion of some of the most helpful research. There is then a list of the most important medical articles so that
you can read further if you want to – most of this is freely available online, at least in summary form.
A few notes on the individual sections:
1. This section is about how much dialysis a patient should have. The effectiveness of dialysis varies between
patients because of differences in body size and age etc., so different people need different amounts, and this
section gives guidance on what defines “enough” dialysis and how to make sure each person is getting that. Quite
a bit of this section is very technical, for example, the term “eKt/V” is often used: this is a calculation based on blood
tests before and after dialysis, which measures the effectiveness of a single dialysis session in a particular patient.
2. This section deals with “non-standard” dialysis, which basically means anything other than 3 times per week.
For example, a few people need 4 or more sessions per week to keep healthy, and some people are fine with
only 2 sessions per week – this is usually people who are older, or those who have only just started dialysis.
Special considerations for children and pregnant patients are also covered here.
3. This section deals with membranes (the type of “filter” used in the dialysis machine) and “HDF”
(haemodiafiltration) which is a more complex kind of dialysis which some doctors think is better. Studies are still
being done, but at the moment we think it’s as good as but not better than regular dialysis.
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4. This section deals with fluid removal during dialysis sessions: how to remove enough fluid without causing cramps
and low blood pressure. Amongst other recommendations we advise close collaboration with patients over this.
5. This section deals with dialysate, which is the fluid used to “pull” toxins out of the blood (it is sometimes
called the “bath”). The level of things like potassium in the dialysate is important, otherwise too much or too
little may be removed. There is a section on dialysate buffer (bicarbonate) and also a section on phosphate,
which occasionally needs to be added into the dialysate.
6. This section is about anticoagulation (blood thinning) which is needed to stop the circuit from clotting, but
sometimes causes side effects.
7. This section is about certain safety aspects of dialysis, not seeking to replace well-established local protocols,
but focussing on just a few where we thought some national-level guidance would be useful.
8. This section draws together a few aspects of dialysis which don’t easily fit elsewhere, and which impact on
how dialysis feels to patients, rather than the medical outcome, though of course these are linked. This is where
home haemodialysis and exercise are covered.
There is an appendix at the end which covers a few aspects in more detail, especially the mathematical ideas.
Several aspects of dialysis are not included in this guideline since they are covered elsewhere, often because they
are aspects which affect non-dialysis patients too. This includes: anaemia, calcium and bone health, high blood
pressure, nutrition, infection control, vascular access, transplant planning, and when dialysis should be started.
Introduction
Haemodialysis continues to expand in the UK with over
25 000 patients now being treated, representing a 10%
increase since publication of the previous Renal Associ-
ation guideline for haemodialysis. In addition the patient
group continues to develop: the typical patient is now 67
years old with a median history of 3.2 years on renal re-
placement therapy. The authors of this guideline aimed
principally to update the previous guideline according to
the latest research and experience, but also to expand
the scope into areas not previously covered but relevant
to haemodialysis practice.
The guideline was written collaboratively: lead and co-
authors for each section conducted literature reviews and
wrote first drafts of the statements and rationale. Feedback
and discussion were provided by all authors via email ex-
changes and meetings, revised versions were produced
with editorial input from the chair, and these were subse-
quently agreed by all authors. Two current haemodialysis
patients gave advice on tone and readability.
Systematic literature searches were undertaken by lead
authors to identify all relevant evidence published up until
the end of June 2018. Compound search terms were used
which included a dialysis identifier (hemodialysis[tiab] OR
haemodialysis[tiab] OR dialysis[tiab]) followed by title/ab-
stract-filtered topic terms (“dialysis dose”, Kt/V, augmented,
intensive, conservative, incremental, pregnancy, membrane,
hydration, “dry weight”, “fluid overload”, dialysate, potas-
sium, bicarbonate, buffer, phosphate, “dialyser reaction”,
hypersensitivity, “blood loss”, “needle dislodgment”, exsan-
guination, “home haemodialysis”, “nocturnal haemodialy-
sis”, exercise, “physical training”) followed by negative
terms (e.g. to exclude animal studies and acute kidney
injury) finally with date and language restrictions (“1990/
01/01”[dp]: “3000”[dp] AND english[lang]). Searches were
conducted in MEDLINE, PUBMED, Embase, and The
Cochrane Library, and supplemented with papers hand-
picked from the reference lists of review papers.
The strengths of the recommendations and the level of
supporting evidence are coded as previously using the
Modified GRADE system.
There are a few changes in scope, for example dialysis
water treatment is now covered in another guideline, as
are many aspects of dialysis, including:
 Planning, initiation & withdrawal of Renal
Replacement Therapy
 Vascular Access for Haemodialysis
 Cardiovascular Disease
 Blood Borne Viruses
 Assessment of the Potential Kidney Transplant
Recipient
 Nutrition
 Anaemia
 CKD-Mineral and Bone Disorder
 Water Treatment Facilities, Dialysis Water and
Dialysis Fluid Quality
We have removed the section on targets for blood test-
ing since these are better covered in other guidelines, and
have not covered infrastructure or workforce since these
will be addressed separately by the Renal Association in a
different format.
However, in most ways the update is broader than previ-
ous versions. For example, new sections have been written
covering fluid management (surely an essential topic but
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not really covered previously or elsewhere) and dialysate
(often underestimated in importance). In other areas this
update seems to make no substantial change to previous
guidance (as with dialysis dose, for example, where the lit-
erature remains dominated by previous large trials), how-
ever whilst key concepts remain valid, their understanding
has developed, and the guideline aims to provide greater
context, encouraging a more holistic interpretation.
Discussions about dialysis often become overly technical –
these concepts are important but hard to fit into a narrative
so we have moved a few aspects into the appendix, where
we aim to provide simplified summaries. We have tried to
maintain a high standard of readability since conceptual un-
derstanding is the key goal, and as the guideline is not
intended to replace review articles or original papers, it
seems correct to favour readability over detail.
Summary of clinical practice guidelines
Dialysis dose in thrice weekly dialysis schedules
We recommend eKt/V as the most clinically valid small-
solute measure of dialysis dose, and recommend monitor-
ing of dialysis dose on a monthly basis for the majority of
centre-based dialysis patients. [1B]
We recommend targeting dialysis dose to achieve con-
sistently a minimum eKt/V of 1.2 for thrice weekly pa-
tients, in the absence of a measured contribution from
residual function. [1B]
We recommend a minimum of 12 hours per week for
the majority of thrice weekly patients with minimal re-
sidual function. [1B]
Non-standard schedules (Guidelines 2.1 – 2.4)
Guideline 2.1 - Augmented schedules
We suggest offering an augmented schedule to patients
who are unable to achieve adequacy targets or fluid con-
trol on a standard thrice weekly schedule. [2B]
We suggest that relative contraindications to aug-
mented schedules should be considered, such as signifi-
cant residual function or problematic fistula access. [2C]
Guideline 2.2 - Incremental schedules
We suggest that lower haemodialysis dose targets may
be optimal in patients with significant residual renal
function. [2D]
We recommend that residual renal function should be
quantified intermittently in patients on incremental dia-
lysis schedules. [1D]
Guideline 2.3 - Conservative schedules
We suggest that lower haemodialysis dose targets may
be optimal when quality of life is the primary goal of
treatment, rather than longevity. [2D]
Guideline 2.4 - Paediatric schedules
In children and adolescents we recommend an approach
to the assessment of dialysis adequacy which goes be-
yond biochemical targets, incorporating clinical goals
such as growth, bone health, cardiac function and qual-
ity of life. [1C]
We recommend targeting dialysis dose to achieve a mini-
mum eKt/V of 1.2 for thrice weekly patients, or a standard-
ized Kt/V of 2.2 for those on augmented schedules. [1C]
We suggest an augmented schedule for children on
predominantly liquid nutrition, and those with ventricu-
lar systolic dysfunction. [2D]
We recommend a blood flow rate of 5-7ml/kg/min for
the majority of patients, using consumables appropriate
to body size, with extracorporeal volume less than 10%
of the patient’s blood volume. [1C]
Guideline 2.5 -Schedules during pregnancy
We recommend counselling women of reproductive age
who are receiving or anticipating dialysis, so that they
are aware of the interactions between renal replacement
therapies and pregnancy which may impact on family
planning and modality decisions. [1D]
For dialysis patients wishing to continue their preg-
nancy, we recommend changing as early as possible to
an individualised, augmented haemodialysis schedule.
For those with minimal residual function this should be
at least 20 hours per week, delivered over at least 6 ses-
sions. [1B]
We recommend an individualised dialysate prescrip-
tion appropriate to the dialysis schedule and biochemis-
try results, anticipating the frequent need for a high
potassium / low bicarbonate dialysate, supplemented
with phosphate. [1C]
We suggest an individualised fluid management proto-
col, with low ultrafiltration rates and regular clinical as-
sessment, anticipating the typical change in weight
during pregnancy. [2C]
Membrane flux and haemodiafiltration
We recommend that patients with minimal residual
function should be treated with high-flux dialysers. [1B]
We suggest that haemodiafiltration may be considered
as a treatment for intra-dialytic hypotension refractory
to other measures, and for dialysis patients with
favourable prognosis who are unable or unlikely to be
transplanted. [2B]
Fluid in haemodialysis (Guidelines 4.1 – 4.2)
Guideline 4.1 - Fluid assessment and management in adults
We recommend assessment of fluid status when prompted
by clinical circumstances, and on a quarterly basis for stable
patients. [1C]
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We suggest a multidisciplinary approach to fluid as-
sessment, with patient involvement and the adoption of
patient-friendly terminology such as “target weight”,
“fluid gain” and “over-hydration”. [2D]
We recommend clinical assessment of fluid status on a
monthly basis for the majority of patients. [1C]
We suggest supplementing clinical assessment of fluid
status with a validated objective measurement, such as
bioimpedance, at regular intervals, when clinical assess-
ment is unclear, and following an intercurrent illness. [2C]
We recommend a dialysate temperature not greater
than 36'C if standardised. [1C]
We recommend avoiding excessive ultrafiltration rates
by addressing fluid gains, accepting staged achievement
of target weight, or using an augmented schedule, as ne-
cessary. [1B]
We recommend prompt nursing intervention to re-
store haemodynamic stability in symptomatic / severe
intradialytic hypotension, with such interventions lead-
ing to clinical review. [1C]
Guideline 4.2 - Paediatric fluid considerations
In growing children we recommend clinical assessment
of fluid status and target weight, and dietetic assessment,
at least monthly. [1C]
We suggest supplementing clinical assessment with a
validated objective measure of fluid status such as bioim-
pedance, on a monthly basis or more frequently during
periods of rapid growth or illness. [2C]
We recommend regular assessment of ultrafiltration
tolerance, using extended times to avoid excessive ultra-
filtration rates. [1D]
Dialysate (Guidelines 5.1 – 5.4)
Guideline 5.1 -Selection of dialysate potassium
We recommend an optimal pre-dialysis serum potas-
sium in the range 4.0–6.0mmol/L, remembering to con-
sider measurement errors (e.g. due to haemolysis) when
interpreting levels. [1B]
We suggest choosing dialysate potassium between 1.0
and 3.0mmol/L for the majority of patients, using an
individualised approach, in general using the highest di-
alysate potassium that is sufficient to control pre-dialysis
hyperkalaemia. [2C]
We suggest a combined approach to managing hyper-
kalaemia, which may include decreasing dialysate potas-
sium and/or other measures, including dietary advice,
medication review and increased dialysis frequency. [2D]
Guideline 5.2 - Selection of dialysate buffer
We recommend an optimal pre-dialysis serum bicarbon-
ate in the range 18.0-26.0mmo/L, remembering to con-
sider measurement errors (e.g. due to exposure to air)
when interpreting levels. [1C]
We suggest the term ‘dialysate buffer’ rather than ‘di-
alysate bicarbonate’ to avoid confusion arising from dif-
ferences in manufacturers’ terminology. [2C]
We suggest choosing dialysate buffer below or equal
to 37.0mEq/L for the majority of patients, using a stan-
dardised or individualised approach. [2C]
We suggest a combined approach to abnormal pre-
dialysis serum bicarbonate, which may include increas-
ing dialysis dose, oral bicarbonate, nutritional support,
or individualising dialysate buffer. [2D]
Guideline 5.3 - Supplementation of dialysate with
phosphate
We suggest considering supplementation of the di-
alysate with phosphate in patients on augmented dia-
lysis schedules. [2D]
Guideline 5.4 - Paediatric dialysate considerations
We recommend individualisation of dialysate electro-
lyte concentrations, including potassium, buffer and
calcium. [1C]
We suggest an individualised dialysate temperature,
between core temperature and 0.5°C below, with moni-
toring of intradialytic core temperature for neonates and
smaller children. [2D]
Anticoagulation
We recommend that patients without increased bleeding
risk should be given unfractionated or low-molecular-
weight heparin during dialysis to reduce clotting of the
extracorporeal system. [1A]
We recommend that systemic anticoagulation should
be omitted or minimised in patients with increased
bleeding risk. [1C]
We recommend that patients with heparin allergies
should be prescribed a non-heparin form of anticoa-
gulation. [1A]
Adverse events during dialysis (Guidelines 7.1 – 7.3)
Guideline 7.1 - Routine blood loss
We suggest that during washback, dialysis lines and dia-
lyser are observed to ensure residual blood loss is kept
to a minimum. [2C]
Guideline 7.2 - Disconnection haemorrhage
We recommend maintaining awareness of the risk of
disconnection, the limitations of pressure alarms, and
importance of direct observation, through a program of
education, including patients and carers. [1D]
We suggest regular assessment of individual risk, so
that high risk patients can have enhanced monitoring,
which could include specific devices. [2B]
Ashby et al. BMC Nephrology          (2019) 20:379 Page 4 of 36
Guideline 7.3 - Immune reactions during dialysis
We recommend that dialysis staff should be aware of the
features and management of dialysis reactions, and
should have access to a range of dialyser types. [1C]
Patient experience of dialysis (Guidelines 8.1 – 8.4)
Guideline 8.1 - Home haemodialysis
We recommend that home haemodialysis should be
available in all units as part of a comprehensive renal re-
placement therapy programme. [1A]
We suggest training patients and/or care partners to
achieve a defined set of competencies, using an indivi-
dualised approach to training method and speed. [2D]
We suggest units form a contract with patients outlin-
ing responsibilities, including an agreement to dialyse as
per prescription and trained technique, and including a
policy for re-imbursement of directly arising patient
costs. [2D]
We suggest supporting patients with a specific team
including nephrologists, technicians, and nurses, with
rapid access to dialysis in-centre when required. [2C]
We suggest an agreed individualised prescription for
home haemodialysis, taking into account lifestyle goals,
with the same dose and time target considerations as
centre-based patients. [2C]
We recommend enhanced safety measures for patients
who dialyse alone or overnight, and an enhanced risk as-
sessment for patients with blood-borne viruses. [1C]
Guideline 8.2 - Shared haemodialysis care
We suggest that all centre-based haemodialysis patients
should have opportunity and encouragement to learn as-
pects of their dialysis treatment, and take an active role
in their care. [2D]
Guideline 8.3 - Intradialytic exercise
We recommend that intradialytic exercise should be avail-
able in all units, as a treatment for enhancing physical func-
tioning, in patients without contraindications. [1B]
We suggest that intradialytic exercise be considered as
a method of enhancing quality of life. [2C]
We suggest that exercise regimes be devised by appro-
priately trained staff. [2C]
Guideline 8.4 - Dialysis experience for children and
adolescents
We recommend that haemodialysis for children and ad-
olescents should be delivered in a dedicated paediatric
dialysis centre or at home, with the involvement of a
paediatric multidisciplinary team. [1C]
We recommend that adolescents should commence an
active transition programme by 14 years, or at the time
of presentation in those already over 14. [1D]
Summary of audit measures
Audit Measure 1: Amongst thrice-weekly patients on
dialysis for more than a year, the median eKt/V, and
proportion achieving eKt/V at least 1.2.
Audit Measure 2: Amongst thrice-weekly patients on
dialysis for more than a year, the median dialysis time
per week, and proportion receiving at least 12 hours.
Audit Measure 3: The proportion of patients dialysing 4
or more times per week (either in-centre or at home).
Audit Measure 4: The proportion of patients dialysing
less than 3 times per week, separated into: (a) patients
in their first year of dialysis, and (b) patients on dialysis
for more than a year.
Audit Measure 5: The median ultrafiltration rate, and
proportion of patients with residual kidney function
(Kru > 2ml/min, or urine volume > 500ml/d), separated
into: (a) patients in their first year of dialysis, and (b)
patients on dialysis for more than a year.
Audit Measure 6: The proportion of patients receiving
haemodiafiltration, and the median convection volume
in this group.
Audit Measure 7: The most commonly used dialysate
sodium level, and proportion of patients using this
dialysate sodium level.
Audit Measure 8: The availability of an objective tool
for fluid state assessment, the type of tool used most
commonly, and the proportion of patients assessed
with an objective tool during the last year.
Audit Measure 9: The median pre-dialysis serum po-
tassium, and proportion of patients arriving with aver-
age potassium over 6.0mmol/l, and proportion with
average under 4.0mmol/l.
Audit Measure 10: The proportion of patients using a
dialysate potassium level in the following categories:
less than 2.0, 2.0, and more than 2.0mmol/l.
Audit Measure 11: The number of disconnection
haemorrhage events each year.
Audit Measure 12: The proportion of haemodialysis
patients having all or most of their dialysis at home.
Audit Measure 13: The proportion of in-centre pa-
tients recognised as engaging in “Shared Care”.
Audit Measure 14: The availability of a program for
intra-dialytic exercise, the resource available (equip-
ment, physiotherapist time), and the proportion of in-
centre patients engaging with regular intra-dialytic
exercise.
Rationale for Clinical Practice Guidelines
Dialysis dose in thrice weekly dialysis schedules
We recommend eKt/V as the most clinically valid small-
solute measure of dialysis dose, and recommend monitor-
ing of dialysis dose on a monthly basis for the majority of
centre-based dialysis patients. [1B]
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We recommend targeting dialysis dose to achieve con-
sistently a minimum eKt/V over 1.2 for thrice weekly pa-
tients, in the absence of a measured contribution from
residual function. [1B]
We recommend a minimum of 12 hours per week for the
majority of thrice weekly patients with minimal residual
function. This may lead to higher than minimum eKt/V in
smaller adult patients which is appropriate. [1B]
Rationale
Dialysis adequacy encompasses concepts including the
clinical assessment of general wellbeing, fluid status, and
control of laboratory parameters, along with quantifica-
tion of the dose of dialysis provided.
The purpose of dialysis is to provide enough removal of
uraemic solutes and fluid that accumulate in kidney failure
to maintain health and quality of life: more specific goals
include control of uraemic symptoms, maintenance of safe
electrolyte levels, prevention of nutritional decline, and
optimum long term mortality. Whilst the earlier items in
this list are readily assessed over a short time scale, con-
cepts of dialysis dose are required to define the amount of
dialysis likely to achieve longer term goals of treatment.
Due to the simplicity and low cost of measurement of
urea in blood, measurement of dialysis adequacy has his-
torically focused on clearance of small solutes, repre-
sented by urea. Concentration of a range of uraemic
toxins of larger size (e.g. β-2 microglobulin) is likely to
be important, but their measurement is not commonly
performed. Use of thrice weekly haemodialysis schedules
emerged from the realisation during the early era of
haemodialysis treatment that once or twice-weekly
haemodialysis schedules in patients with minimal re-
sidual function was insufficient to control the symptoms
and complications of severe uraemia.
Most research on dialysis dose is therefore based on
urea clearance, in patients on a thrice weekly schedule.
Urea clearance may be calculated by three methods in
common use: Urea Reduction Ratio, and the ‘single pool’
and ‘equilibrated’ formulas for Kt/V. Kt/V is less commonly
calculated by Urea Kinetic Modelling - these methods are
summarised mathematically in Appendix 1. The diversity of
methods can lead to duplication of effort, confusion over
the meaning of targets, and impedes comparison between
centres, so a single widely used method would be desirable.
As the most adjusted method, and the one which has been
most commonly validated in outcome literature, eKt/V ap-
pears to be optimum, and we have therefore given dose tar-
gets in terms of eKt/V. Equivalent targets using other
methods may be derived for individual patients depending
on their dialysis duration and fluid removal.
The literature on clinical outcome at different doses of
dialysis is dominated by two randomised studies. The
National Cooperative Dialysis Study (NCDS) was the
landmark study which led to the concept of a threshold dia-
lysis dose above which treatment was adequate, as well as
the establishment of Kt/V as the accepted index of dialysis
dose. Reporting in 1981, the study randomised 151 patients
in a 2x2 design to high vs low time-averaged urea, and
short vs long dialysis duration - the key finding was a lower
rate of treatment failure (death or hospital admission) in
the low urea (high dialysis dose) group [1]. When reanalys-
ing the group with the newly proposed Kt/V measure, a
clear threshold effect appeared, with Kt/V defining the
watershed between ‘adequate’ and inadequate dialysis (Kt/V
over vs under 1.0) [2].
A large number of observational studies subsequently re-
ported an association between higher dialysis doses (beyond
merely achieving the NCDS threshold) and improved sur-
vival [3–6], and this was tested in the HEMO study. Report-
ing in 2002 the HEMO study randomised 1846 patients in
another 2x2 design to high vs standard dialysis dose (eKt/V
1.45 vs 1.05) and high vs low flux [7]. Over 2.8 years follow-
up with groups well separated in terms of achieved eKt/V
(1.53 vs 1.16), higher dose provided no benefit in terms of
survival or a number of secondary endpoints.
The basic concepts of these studies have not been su-
perseded, hence the recommendation for dialysis dose
(eKt/V > 1.2) is based largely on the eKt/V achieved in
the standard dose group of the HEMO study. Alternative
measures such as URR or spKt/V may be more familiar
to some clinicians and equally useful for the majority of
patients. Equivalent thresholds using these parameters
are approximate since they vary between patients, but
the differences are small: Appendix 1 summarises the
mathematics behind these concepts.
Whether ‘adequate’ dialysis is the same for all patients or
whether dose should be individualised is unclear, but the
latter view is supported by several studies suggesting that
gender and body size may affect the optimum dialysis dose
[8–10]. Observational studies suggest that dialysis dose is
more strongly related to survival in women than men, and
when the HEMO study analysis is restricted to women, the
high dose group show significantly improved survival. The
reason for this interaction between gender and optimum
eKt/V is unknown, but may be due to the scaling parameter
‘V’, which is lower in women and in less muscular patients,
and is an independent predictor of survival. Alternative
scaling factors such as body surface area, have been sug-
gested [11–14], but none is in widespread use, and the col-
linearity between different body size parameters makes
analyses difficult to interpret, but it seems likely that the
optimum Kt/V may be higher than 1.2 in women and
smaller patients, without a clear definition of ‘small’ [15].
Dialysis time
The optimum treatment duration for thrice weekly
haemodialysis is slightly less clear, since it is difficult
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to separate the effect of treatment time from dialysis
dose [16].
The evolution of dialysis technology has made dialysis
dose targets achievable over short dialysis sessions. How-
ever, there are uraemic solutes other than urea, such as
phosphate and β2-microglobulin, which are also import-
ant predictors of outcome, and which are inefficiently
removed by dialysis [17, 18]. Extending dialysis duration
increases the removal of these highly sequestered and
larger molecules, independent of any change in small
solute clearance [19, 20]. In the other part of its 2x2 de-
sign, the NCDS study also compared session duration
(4.5-5.0 vs 2.5-3.0 hours) and although standard signifi-
cance ‘level’ was not achieved (p=0.06), showed reduced
treatment failure in the longer session group [1].
Most observational studies also report improved out-
comes with longer treatment times. Low mortality rates
were reported from Tassin with 8 hour overnight dialy-
sis, attributed to improved blood pressure control and
slower ultrafiltration [21, 22], and lower mortality is as-
sociated with longer treatment times in national registry
studies (over vs under 3.5 hours in US patients [23], and
over vs under 4.5 hours in Australia [24]). The inter-
national DOPPS study examined the effect of treatment
time whilst controlling for confounders using standard
regression and instrumental variable approaches, con-
cluding that patients with the longest treatment time (at
least 4 hours) had the lowest risk for all-cause and car-
diovascular mortality [25]. Other clinical markers such
as blood pressure, anaemia and phosphate control were
also improved.
Whilst recognising the limitations of observational
studies, a minimum duration for optimum dialysis
clearly exists, and is most likely close to 4 hours, at least
for patients with minimal residual kidney function. A
duration threshold may lead to higher than minimum
eKt/V in smaller adult patients, which is appropriate
since optimal Kt/V may be higher in this group.
Summary
Optimal outcomes in patients on thrice weekly dialysis are
achieved with sessions of at least 4 hours, providing eKt/V
at least 1.2. Regular monitoring is strongly recommended,
and this occurs monthly in the majority of units.
Under achievement may be addressed by attention to
vascular access [26], session duration [27], blood or di-
alysate flow [28–30], dialyser efficiency [31] or anticoa-
gulation [32], and in some patients under achievement
may suggest the need for an augmented schedule.
Achievement of these targets does not guarantee optimal
outcome, with eKt/V being unaffected by missed ses-
sions, for example.
These dose targets apply to thrice weekly patients, with
minimal residual function, for whom survival duration is a
primary treatment goal. There are specific clinical scenar-
ios and different patient values for which it may be appro-
priate to adjust or disregard numeric targets for dialysis
dose.
Non-standard schedules (Guidelines 2.1 – 2.4)
Guideline 2.1 - Augmented schedules
We suggest offering an augmented schedule to patients
who are unable to achieve adequacy targets or fluid con-
trol on a standard thrice weekly schedule. [2B]
We suggest that relative contraindications to aug-
mented schedules should be considered, such as signifi-
cant residual function or problematic fistula access. [2C]
Rationale
Dialysis dose on a thrice weekly schedule is limited by
patient tolerance and the necessity to utilise ‘slots’ effi-
ciently, so that sessions over 5 hours are very uncom-
mon. ‘Augmented’ in this guideline refers to increased
frequency (4-6 sessions per week) or thrice weekly dialy-
sis totalling more than 15 hours per week. The latter is
usually delivered nocturnally when in-centre, but both
are often delivered in the context of home haemodialysis
where much of the evidence regarding augmented dialy-
sis schedules has been obtained.
Augmented schedules have been assessed in four ran-
domised studies [20, 33–35], one interventional study
with matched controls [36], and a handful of observa-
tional studies. Evidence of clinical benefit limited to
interventional studies is summarised below, with studies
divided into three groups for ease of discussion, accord-
ing to the type of augmented schedule [20, 33–37]. A
fourth group of augmented schedules which might be
termed ‘modestly frequent’ (4 or 5 sessions per week, of
up to 4 hours each) is poorly represented in studies.
Group Frequent
nocturnal
Short daily Nocturnal
Definition > 6 x/week
> 6 hours
> 6 x/week
< 4 hours
3 x/week
> 6 hours
Lead author / study type
(patient number in
intervention group)
Culleton /
RCT (26)
Rocco / RCT
(45)
Chertow /
RCT (125)
Ok / NRI
(247)
Ipema
(metanalysis)
Left ventricular mass Decreased
(Culleton)
No change
(Rocco)
Decreased
Blood pressure Improved Improved Improved
Hyperphosphatemia Improved Improved Improved
Nutritional status Improved
Composite health score /
quality of life
No change Improved
Abbreviations: RCT randomized controlled trial, NRI non-randomised
intervention
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Where assessed, improvements in depression, cognition
or anaemia parameters were generally not seen in these
studies, although improvements in these aspects have
been reported in a number of observational studies.
Quality of life is an important outcome since the
intervention clearly involves increased treatment burden.
Observational studies suggest that quality of life of life is
improved in daily dialysis by approximately 6%, whereas
nocturnal schedules have not been show to improve
quality of life [38–40].
The randomised studies were not designed primarily
to assess mortality within the study period, but two of
these published mortality results with follow-up ex-
tended by approximately 2.5 years [41, 42], and mortality
effects have also been reported in other types of study.
Findings have been surprisingly inconsistent, however,
and are summarised in the table below [36, 41–45].
Group Frequent
nocturnal
Short daily Nocturnal
Definition > 6 x/week
> 6 hours
> 6 x/week
< 4 hours
3 x/week
> 6 hours
Lead author / study type
(patient number on
augmented schedule)
Rocco / RCT
(45)
Chertow / RCT
(125)
Marshall / OS
(?)
Suri / OS (318)
Ok / NRI
(247)
Rivara / OS
(1206)
Hazard ratio for mortality
(less than 1.0 favours
augmented schedule)
3.88 0.54
1.00 / 0.41 (unit
/ home)
1.60
0.28
0.67
Abbreviations: RCT randomized controlled trial, NRI non-randomised
intervention, OS observational study
Authors stress that clinical trials of more intensive
dialysis were not designed to evaluate mortality, and that
observational analyses often employ statistical
techniques which do not adequately address the time-
varying nature of the risk factors associated with both
the initiation of augmented dialysis and mortality.
The larger randomised trials of augmented schedules
have also identified potential harms, for example
reducing residual function, an important determinant of
survival on haemodialysis. In patients who had
significant residual function at enrolment, both frequent
nocturnal and short daily dialysis led to a more rapid
decline in function compared to control groups [46].
Intervention patients had a shorter time to first vascular
access intervention, and there were small increases in
the burden on carers, as perceived by patients, though
the authors highlight that carers themselves were not
assessed [47].
Taken together these studies suggest equivalent
mortality and modest improvement in some dialysis-
related conditions, offset by increased treatment burden
and possible harms to vascular access and residual func-
tion. Whilst there is no overall advantage for the average
patient these studies do suggest specific groups who
would be expected to benefit. For example, adequacy
targets could certainly be achieved in those still unable
to, despite a reasonably long thrice weekly schedule.
Similarly, patients failing to achieve fluid control are
likely to benefit from an increase in dialysis frequency -
this might include those with resistant hypertension,
intra-dialytic hypotension, and those with weekend ad-
missions to hospital. The latter group are the obvious
contributors to the excess mortality of the two-day dialy-
sis gap, and may have the most to gain from an increase
in dialysis frequency. The augmentation of dialysis in
these settings should be aimed at achieving a specific
purpose, and it is likely that a fourth session per week
would be sufficient in many cases.
In conclusion, augmented schedules offer no clear
advantage for the majority of patients, but should be
considered as a treatment option for those patients
whose adequacy or fluid control targets are not met with
a standard schedule. A modestly augmented schedule
would be sufficient in the majority of these patients.
Guideline 2.2 - Incremental schedules
We suggest that lower haemodialysis dose targets may
be optimal in patients with significant residual renal
function. [2D]
We recommend that residual renal function should be
quantified intermittently in patients on incremental
dialysis schedules. [1D]
Rationale
Incremental haemodialysis is based on the common sense
concept that the amount of dialysis required for optimal
outcome differs between those with significant residual
function and those without. The latter group however is
larger, and makes up the majority in studies of dose and
outcome, which therefore may not be applicable in the
former group. Optimal dialysis dose is therefore not fixed
but dependent on the level of residual kidney function,
and the prescribed schedule may therefore be reduced in
frequency or dose in this setting. The practice of
incremental haemodialysis is consistent with a concept of
progressively increasing therapy over time, which may
include augmented schedules at a later stage (Fig. 1).
Less frequent and reduced dose dialysis practices co-
evolved along with standard thrice-weekly schedules: ref-
erence is made to twice weekly dialysis in observational
studies from the 1990s and in the 1997 KDOQI guide-
lines [48]. For example, in an observational study of 15
000 American patients published in 1999, Hanson re-
ported twice weekly schedules in 6.1% of patients during
their first year, and 2.7% of patients thereafter [49]. Out-
comes were at least as good, and in fact a mortality ad-
vantage was observed with twice weekly schedules, most
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likely due to differences in baseline factors: no mortality
difference was seen after adjustment for the level of re-
sidual function at dialysis initiation.
The non-inferiority of twice weekly schedules in selected
patients has been further supported by more recent stud-
ies. In a Thai study of 500 twice-weekly patients Panaput
reported equivalent mortality and hospitalisation over the
next year [50], and in a propensity-matched Korean study
of 300 patients followed for one year, Park reported
equivalent mortality and improved quality of life with
schedules less than thrice-weekly [51]. Non-inferiority of
clinical outcome with reduced treatment burden therefore
provides a powerful argument in favour of incremental
schedules, but additional benefits may exist: incremental
haemodialysis schedules have also been associated in some
observational studies with reduced decline in residual kid-
ney function [52, 53].
Preservation of residual function is of clinical importance
since it provides significant solute and fluid removal, and is
associated with improved quality of life and survival [54].
The literature on incremental schedules is limited in
particular by its observational nature, with inherent
problems of selection and lead-time bias. Variation also
exists in the definition of incremental dialysis, which is
frequently defined as twice-weekly, without reference to
residual function. Clinician bias may also be important:
clinicians working in the 1990s will remember twice-
weekly schedules principally as a resource-sparing exer-
cise, and even in modern series, financially constraints
play a part in their use [55].
Patient selection is therefore crucial: factors currently
associated with reduced schedule use in a large Chinese
study include early vintage, female sex and minimal
comorbidity [56]. And the level of residual function appears
perhaps unsurprisingly to be the most important factor: in
a large American study in which 350 twice-weekly patients
were matched with a thrice-weekly group, twice-weekly
schedules yielded equivalent one year outcome in many,
but were clearly inferior in those with the poorest residual
function (clearance less than 3ml/min/1.73m2) [57]. Those
with residual clearance of 3ml/min or less may still be suit-
able for a thrice-weekly incremental schedule (i.e. with dose
target less than Kt/V 1.2 and/or less than 4 hours).
The use of incremental haemodialysis therefore
requires regular monitoring of residual function, with
function reassessed after major intercurrent illness [58].
Suitable patients should be aware that dialysis duration
is likely to increase over time, and should be willing to
cooperate with residual function measurements [59].
Incremental dialysis is entirely consistent with the
concepts of adequate dialysis dose established in the NCDS
and HEMO studies as discussed in Section 1, but
incorporates the contribution of residual function, so that
dialysis and residual function are seen as both contributing
to overall clearance. There are a number of different
methods for quantifying combined kidney and dialysis urea
clearance (summarised in Appendix 2) which can help with
schedule and dose selection. These should be interpreted in
clinical context, with due observation of indirect measures
of dialysis adequacy such as control of symptoms, blood
pressure, fluid gains and electrolytes, so that dialysis dose
can be appropriately escalated if treatment appears clinically
inadequate.
Guideline 2.3 - Conservative schedules
We suggest that lower haemodialysis dose targets may
be optimal when quality of life is the primary goal of
treatment, rather than longevity. [2D]
Fig. 1 Schematic to illustrate principle of incremental haemodialysis (numbers only as examples)
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Rationale
Whilst concepts of dialysis dose have been developed over
the last two decades, the dialysis population has been
changing, with the median age of the prevalent dialysis
population increasing by nearly 20 years, and diabetes
becoming one of the leading causes of established kidney
failure. For many patients, dialysis is a long-term mainten-
ance therapy that continues until death or dialysis with-
drawal, with increasing comorbidity and frailty developing
during this time [60].
This changing demographic has important implications
for the clinical application of dialysis dose. Firstly, studies
have typically focused on younger patients (median age 49
in the NCDS study including no diabetics, and mean age
58 in the HEMO study) so that applying their conclusions
in a more elderly group is an extrapolation. Secondly,
studies are generally more concerned with mortality, and
many strategies in dialysis are aimed at preventing future
complications, whereas current symptoms and quality of
life are often more relevant to the frailer patient. And
thirdly, the burden of dialysis often increases with
increasing frailty, so that there is a greater trade-off when
considering the burden versus the benefit of treatment. In
the context of this changing demography, it is reasonable
to question whether conventional dialysis dosing and tar-
gets remain appropriate for this population [61].
Frailty as a clinical syndrome can be defined when a
number of factors are present including: unintentional
weight loss, self-reported exhaustion, weakness and low
physical activity. The presence of frailty is associated
with increasing disability and hospitalisation, and in dia-
lysis patients, with an adverse quality of life irrespective
of dialysis modality.
The optimum dialysis for frail patients has only been
studied in small cohorts. Some overlap exists between the
features of frailty and those of underdialysis, and it could
be argued be that more intensive dialysis might better
control some aspects such as fluid overload, intradialytic
hypotension or sarcopenia, or conversely that nutritional
decline might be accelerated by reduced dialysis.
Reductions in dialysis quantity should therefore not be
misunderstood as a method of improving these aspects of
frailty. However, while increasing hours or frequency of
dialysis may theoretically overcome some of these
problems, patients often perceive the burden of dialysis on
their quality of life more than the symptomatic benefit,
and dialysis itself may confer specific harms in this group:
a retrospective study identified frequent functional
deterioration among dependent patients following the
initiation of dialysis [62].
In a challenging clinical area with a paucity of outcome
data, it therefore seems entirely appropriate to reduce or
disregard numeric targets for dialysis dose, instead
individualising dialysis according to specific patient goals.
Goal-oriented care is an established approach in patients
with multiple co-morbidities which overcomes the prob-
lems inherent in disease-specific care processes, with dis-
cussions instead concentrating on a patient’s individual
aims of treatment.
Shared discussions about dialysis schedule, driven by
patient-centred goals can ensure that patients are neither
under or over-treated, and in some cases might be a pre-
cursor to dialysis withdrawal. Such discussions may need
frequent review following changes in the patient’s clin-
ical or personal circumstances.
Guideline 2.4 - Paediatric schedules
In children and adolescents we recommend an approach
to the assessment of dialysis adequacy which goes
beyond biochemical targets, incorporating clinical goals
such as growth, bone health, cardiac function and
quality of life. [1C]
We recommend targeting dialysis dose to achieve a
minimum eKt/V of 1.2 for thrice weekly patients, or a
standardized Kt/V of 2.2 for those on augmented
schedules. [1C]
We suggest an augmented schedule for children on
predominantly liquid nutrition, and those with
ventricular systolic dysfunction. [2D]
We recommend a blood flow rate of 5-7ml/kg/min for
the majority of patients, using consumables appropriate
to body size, with extracorporeal volume less than 10%
of the patient’s blood volume. [1C]
Rationale
The low incidence of dialysis-requiring kidney disease in
childhood, means that many treatment decisions are in-
formed by observational data and studies carried out in
adults. The small-solute dose target for adults (eKt/V over
1.2) therefore has some relevance to children, though cau-
tious interpretation of a target extrapolated from a differ-
ent clinical setting would lead many clinicians to aim for a
more conservative (i.e. higher) target dose. In addition,
unique physiological aspects of childhood, such as growth,
may be improved by increased dialysis dose, and there are
strong arguments to suggest that optimum Kt/V may be
size-dependent in adults, so that a higher minimum Kt/V
may be appropriate [63]. The desirable lower limit for
eKt/V is therefore thought to be between 1.2 and 1.4.
However, as is increasingly recognized now in adults, it
has long been argued that the optimal quantity of dialysis
for children cannot be characterized by a single numerical
measurement [64]. In addition to the desirable clinical
outcomes shared with adults, the therapeutic goals for
children and adolescents receiving dialysis include
achievement of normal growth, bone maturation and social
development, along with avoidance of cardiac compromise
and disrupted education. The increasing evidence that
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dialysis dose and schedule is able to improve cardiac
function and outcomes in many of these domains argues
for a broader concept of “adequacy” which might best be
assessed using a constellation of clinical outcomes, as well
as biochemical targets.
Augmented dialysis, with increased frequency in
particular, is therefore increasingly advised by clinicians,
and despite the obvious drawback of treatment burden,
does not seem to reduce quality of life, even in
adolescents [65]. It is possible that augmented schedules
are optimal for all children, but some groups seem
particularly likely to benefit, including those with cardiac
dysfunction and those on a liquid diet, in whom it might
otherwise be difficult to achieve safe fluid control [66].
Safe limits appropriate to body size are advocated for
many aspects of the extracorporeal circuit, such as a
blood flow rate of 5-7ml/min/kg, which is often ad-
equate to achieve dialysis dose with double needles, with
arterial aspiration pressures below 200mmHg, to limit
endothelial trauma. For single-needle dialysis the highest
blood flow rate is obtained using a double pump system
(venous flow higher than arterial) monitored by pressure
(time pressure regulation), with clamp techniques used
to achieve an acceptable compromise between recircula-
tion and blood flow [67]. Consumables appropriate to
body size should be selected so that total extracorporeal
volume is less than 10% of blood volume, to reduce the
volume load with wash-back at the end of the session.
System priming with albumin or even blood may some-
times be required for babies and small infants.
Guideline 2.5 -Schedules during pregnancy
We recommend counselling women of reproductive age
who are receiving or anticipating dialysis, so that they
are aware of the interactions between renal replacement
therapies and pregnancy which may impact on family
planning and modality decisions. [1D]
For dialysis patients wishing to continue their pregnancy,
we recommend changing as early as possible to an
individualised, augmented haemodialysis schedule. For
those with minimal residual function this should be at least
20 hours per week, delivered over at least 6 sessions. [1B]
We recommend an individualised dialysate prescription
appropriate to the dialysis schedule and biochemistry results,
anticipating the frequent need for a high potassium / low
bicarbonate dialysate, supplemented with phosphate. [1C]
We suggest an individualised fluid management
protocol, with low ultrafiltration rates and regular
clinical assessment, anticipating the typical change in
weight during pregnancy. [2C]
Rationale
Successful pregnancies in women on haemodialysis are
becoming more common: prior to 1995 data from the
USA suggested only 40% infant survival, but outcomes
in the current era are substantially better [68]. However,
pregnancy complications in haemodialysis patients are
still more common than in pre-dialysis and transplant
patients, and may result in HLA sensitisation, so delay-
ing until after transplantation may be favourable for
some. Conception may be more likely with augmented
dialysis schedules [69], but the possibility of pregnancy
or need for contraception should be considered regard-
less of dialysis schedule.
The literature linking haemodialysis prescription to
outcome in pregnant dialysis patients is limited to case
series and systematic reviews [70]. In a recent meta-
analysis of 681 pregnancies in 647 patients between
2000 and 2014, authors found that longer weekly dialysis
duration significantly associated with a lower incidence
of preterm delivery and babies small for their gestational
age [71]. More frequent dialysis was also associated with
fewer small babies. Normalisation of biochemistry and
fluid status appears to give the best outcome, and virtu-
ally every publication advocates intensified dialysis.
The best evidence for this approach to date is the
comparison of data from the Toronto and US registries
of pregnancy in dialysis patients [72]. In women
established on dialysis before becoming pregnant, 11 of
13 pregnancies were successful with at least 36 hours
per week, compared to 22 of 46 with up to 20 hours (p=
0.02). More intensive dialysis was also associated with
reduced preterm delivery and greater birth weight.
Residual kidney function facilitates normalisation of
fluid and electrolytes, so the accelerated loss of residual
function seen with augmented schedules raises concerns
about this approach in women with good urine output
[73]. In the Toronto/US registry study all of the 17
women who started dialysis partway through the
pregnancy had a successful outcome. Since 13 of them
were in the shorter treatment group, it appears that
longer treatment times would have been unnecessarily
burdensome, and possibly detrimental, to patients with
significant residual function. In a comprehensive review
Hladunewich suggested titrating the dialysis dose to
achieve urea 10-15mmol/L after the longest break be-
tween sessions [74]. The authors also provide advice on
adjusting medication, anaemia management and fetal
monitoring which are outside the scope of this guideline.
With augmented schedules dialysate should be
individualised, with high potassium / low buffer often
required. To ensure the needs of foetal skeletal
development are met, low serum calcium and phosphate
should be avoided, which may involve adjustment of
diet, medication and dialysate: supplementation of the
dialysate with phosphate is often necessary. Magnesium
should possibly be monitored in the third trimester,
since low levels may induce uterine contraction.
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Augmented schedules allow patients with minimal
residual kidney function to remain close to their target
weight and avoid high ultrafiltration rates. Fluid status
needs to be assessed frequently during pregnancy, as
there is a high risk of fluid depletion, especially in the
second and third trimester, and bioimpedance and urine
volume may be useful measurements in this setting.
Typical weight gains during a healthy pregnancy range
from around 150g/week during the first trimester, to
around 450g/week during the third trimester.
Membrane flux and haemodiafiltration
We recommend that patients with minimal residual
function should be treated with high-flux dialysers. [1B]
We suggest that haemodiafiltration may be considered as
a treatment for intra-dialytic hypotension refractory to other
measures, and for dialysis patients with favourable prognosis
who are unable or unlikely to be transplanted. [2B]
Rationale
Convective clearance Haemodialysis removes uraemic
toxins by two very different physical processes: diffusion
and convection.
Diffusion is the movement of solutes independent of
solvent when the concentration differs between the two
sides of a membrane. The rate is dependent on the
concentration difference, the diffusion coefficient of the
membrane, as well as the blood and dialysate flows, and
this process is extremely efficient for small solutes, such
as urea. Convection is the movement of those solutes
not excluded by pore size, along with their solvent as it
crosses the membrane. The rate depends on molecular
size and the ultrafiltration rate, and this process is most
important for molecules too large for efficient diffusion,
but still smaller than the membrane pores, often termed
‘middle molecules’ [18].
Convective clearance is therefore a measurable
component of dialysis, which is qualitatively and
quantitatively distinct from urea clearance and treatment
time. Diffusion of a solute is usually quantified by its Kt/V
(Appendix 1) whereas convection is best quantified by its
sieving coefficient and the ultrafiltration rate (Appendix 3).
Ascending quantities of convection are therefore
achieved with low-flux dialysis, high flux dialysis, and hae-
modiafiltration. Historically low-flux dialysis was standard,
in part because it requires less accurate ultrafiltration con-
trol from the dialysis machine - ultrafiltration in standard
low-flux dialysis is simply equal to the fluid removed from
the patient, usually around 2 litres. In high-flux dialysis
pore size is increased, increasing the sieving coefficient for
middle molecules, but also the permeability to water is im-
proved, so that internal filtration (bidirectional movement
of water within the dialyser) becomes significant: net
ultrafiltration of course remains the same, but total ultra-
filtration, all of which contributes to middle molecule
clearance, is greater and may be as much as 10 litres [75].
In haemodiafiltration a large volume of replacement fluid
is given, to allow net ultrafiltration to be increased to
around 20 litres (Appendix 3). There is little difference in
clearance of small solutes between these methods [76].
Of the (over 100) uraemic toxins known, many are
middle molecules (with molecular weight in the range
0.6-60kDa) for which clearance is largely dependent
therefore on convection [18]. Convective quantity does
not improve clearance of all poorly-diffusing molecules,
with phosphate clearance for example, largely un-
affected, but clearance of many, such as β-2-
microglobulin, is progressively increased by high-flux
dialysis and haemodiafiltration [77–79]. A contribution
of convective dialysis quantity to favourable outcome is
strongly suspected.
Membrane flux Several interventional studies give
insight into the impact of membrane flux on dialysis
outcomes, for example in the other part of its 2x2
design, the HEMO study group compared high-flux with
low-flux dialysis [80]. In the whole group (N=1846)
high-flux dialysis did not confer a clear survival advan-
tage (RR 0.92, 95%CI 0.81-1.04) although cardiac mortal-
ity was reduced (RR 0.80, 95%CI 0.65-0.99). In the
roughly one-third (N=577) of patients with over 3.7
years dialysis vintage prior to randomisation, high-flux
dialysis improved survival substantially (RR 0.68, 95%CI
0.53-0.86).
The Membrane Permeability Outcome study randomised
738 incident patients to high vs low-flux dialysis, stratified
by serum albumin (normal vs subnormal) [81]. Over a
mean observation of 3 years, high-flux dialysis reduced
mortality in the low albumin group (N=493, HR 0.63,
95%CI 0.45-0.90) with a less clear reduction in mortality in
the whole group. High-flux was similarly advantageous in
the subgroup with diabetes.
A meta-analysis of 33 studies comparing high-flux
with low-flux dialysis in 3820 patients, found reduced
cardiovascular mortality (RR 0.83, 95%CI 0.70-0.99) and
a less clear reduction in all-cause mortality (RR 0.95,
96%CI 0.87-1.04) [82]. Endotoxin tends to be absorbed
within high-flux membranes, rather than passing
through, and initial concerns that dialysate endotoxin
would be more problematic with high-flux dialysis ap-
pear to have been unfounded [83].
Whilst no study has unequivocally demonstrated the
superiority of high-flux dialysis for survival, there is clear
evidence of improved cardiovascular outcomes, and all-
cause mortality appears to be improved in several sub-
groups [84]. At the same time, evidence of harm is lacking,
all modern machines have accurate ultrafiltration control,
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and membrane costs are now equivalent. Further research
on this question therefore does not seem to be a high
priority.
Haemodiafiltration The effect of haemodiafiltration has
been informed by four randomised controlled studies,
summarised in the table below. In three of these,
marginal but non-significant advantages were seen in
the haemodiafiltration group, with subgroup analysis
suggesting favourable outcome with the highest convec-
tion volumes, though the latter to some extent may re-
flect body size or treatment tolerance [85–87].
A clear advantage with haemodiafiltration was seen in
the ESHOL study, which specified a higher convection
volume of 23 litres, but consequently may be
confounded by subjects’ ability to sustain these volumes,
which is dependent on high blood flow, so that
censoring may be most frequent in the highest risk
patients [88]. Apart from the CONTRAST study [85]
these were all analysed ‘as treated’, with right-censoring
when treatment was discontinued for any reason, leading
to potential bias since endpoints are more likely to be hid-
den in the haemodiafiltration arm. Another criticism con-
cerns the mechanism of the clinical benefit, since middle
molecule levels were not demonstrably improved by hae-
modiafiltration: plasma levels of β-2-microglobulin in-
creased significantly in both arms of the ESHOL study.
Reduced mortality with haemodiafiltration was
observed with pooled analysis of the four studies (HR
0.86, 95%CI 0.75-0.99) due in particular, to a reduction
in cardiovascular events, with authors estimating the
prevention of one cardiovascular death for every 75
patient-years of treatment [89]. However, due to biases
within study designs, considerable doubt over the super-
iority of haemodiafiltration remains [90].
Study name
(location)
Year of main
publication
Number Int
vs Control
Mean age
Interventions
Mean observation
Mortality % Int
vs Control
HR (95%CI) if
significant
CONTRAST
(Europe/Canada)
2012
358 vs 356
64.1
HDF vs low flux
3 years
36.6 vs 38.8
Turkish HDF
(Turkey)
2013
391 vs 391
56.5
HDF vs high flux
1.9 years
13.3 vs 16.6
ESHOL (Spain)
2013
456 vs 450
65.4
HDF vs 92%
high flux
1.9 years
18.6 vs 22.8
0.70 (0.53 - 0.92)
FRENCHIE (France)
2017
190 vs 191
76.2
HDF vs high flux
2 years
18.9 vs 22.5
Haemodiafiltration was also assessed in a DOPPS
study, in which after adjustment, no association between
convection volume and survival was observed [91].
Several of these studies also found a lower frequency of
intradialytic hypotension with haemodiafiltration
compared to the control group, though the authors
acknowledge the difficulty in excluding confounding
factors such as cooling and positive sodium balance [92].
Fluid in haemodialysis (Guidelines 4.1 – 4.2)
Guideline 4.1 - Fluid assessment and management in adults
We recommend assessment of fluid status when
prompted by clinical circumstances, and on a quarterly
basis for stable patients. [1C]
We suggest a multidisciplinary approach to fluid
assessment, with patient involvement and the adoption
of patient-friendly terminology such as “target weight”,
“fluid gain” and “over-hydration”. [2D]
We suggest supplementing clinical assessment of fluid
status with a validated objective measurement, such as
bioimpedance, at regular intervals, when clinical
assessment is unclear, and following an intercurrent
illness. [2C]
We recommend a dialysate temperature not greater
than 36'C if standardised. [1C]
We recommend avoiding excessive ultrafiltration rates
by addressing fluid gains, accepting staged achievement
of target weight, or using an augmented schedule, as
necessary. [1B]
We recommend prompt nursing intervention to
restore haemodynamic stability in symptomatic / severe
intradialytic hypotension, with such interventions
leading to clinical review. [1C]
Rationale
Fluid control is an essential clinical goal of maintenance
haemodialysis, but correct fluid management requires
clinicians to steer between the two competing /
overlapping problems of fluid overload and intra-dialytic
hypotension.
Failure to control fluid overload may lead to obvious
short-term effects including hypertension and breath-
lessness, and nephrology trainees quickly become famil-
iar with the emergency dialysis admission with
pulmonary oedema. In the longer term also, chronic
fluid overload is one of the main drivers of hypertension
and is independently associated with poor outcomes: for
example, in a US study of over 10 000 prevalent haemo-
dialysis patients, Flythe reported clinical outcomes over
2 years’ follow-up, according to achievement of target
weight during the baseline month [93]. Compared to
those achieving within 2kg of target weight on at least
70% of sessions, the 15% of patients frequently
remaining over-hydrated post dialysis had increased
mortality (HR 1.28, 95%CI 1.15-1.43) as did the 7% of
patients who were frequently under-hydrated post dialy-
sis (HR 1.22, 95%CI 1.05-1.40).
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Often competing, though sometimes associated with
fluid control, is intra-dialytic hypotension, which also
has immediate consequences familiar in the dialysis unit,
including dizziness and cramps, as well as more long-
term adverse effects. For example, Sands studied the oc-
currence of intra-dialytic hypotension (defined as a drop
in systolic blood pressure of at least 30mmHg, to below
90mmHg) in 1137 patients in 13 dialysis facilities, over
an average period of 3 months [94]. With this definition,
hypotension complicated 17.2% of sessions, affecting
74.9% of patients at least once, and 16.2% of patients on
at least one third of their sessions. Those most prone to
intra-dialytic hypotension were older, more comorbid
and with lower pre-dialysis blood pressure, with associ-
ated sessional factors including high ultrafiltration vol-
ume and non-achievement of target weight. Outcomes
associated with intra-dialytic hypotension included
shortened survival and increased hospital admission.
The two main treatment parameters by which
clinicians aim to optimise fluid control, are target weight
and ultrafiltration rate.
Since the earliest days of dialysis, setting ultrafiltration to
achieve a set target weight post dialysis, at which the
patient is at their correct volume (or “dry”) has been the
accepted method of maintaining a consistent volume state,
but the method is dependent on accurate estimation of the
correct target weight. Though most often assessed by
clinical examination, the inaccuracy of this method is
widely appreciated so that both overestimation and
underestimation are common, with the former contributing
to hypertension and left ventricular hypertrophy, and the
latter accelerating the loss of residual kidney function and
perhaps risking myocardial stunning.
To improve on clinical assessment, nephrologists at one
time advocated “probing” target weight: gradual reduction
until patients report symptoms suggesting hypovolaemia,
but this may reduce treatment compliance and a more
collaborative approach is more common: where possible,
patients should be asked to participate in monitoring their
fluid status. To this end terminology should be simple and
intuitively understood: for example, when discussing
target weight, the term “dry weight” can give the
impression that the aim is to remove as much fluid as
possible, and “ideal weight” can be confusing as it is also
used to describe the preferred body mass index. Although
less accurate, “hydration” is a more familiar term than
“volume” as a description of fluid status. Stable patients
should be assessed for target weight changes perhaps
quarterly, but staff and patients should be particularly
vigilant when changes in flesh weight are likely, such as
following hospital admission, or when starting nutritional
supplementation. Fluid management often requires input
from a multidisciplinary team, so a documented policy
may ensure that the approach is consistent.
Improvement on clinical assessment using objective
methods for selecting target weight has been sought for a
long time, though no single measurement has so far gained
widespread acceptance. Methods have fallen into one of a
number of categories: imaging (such as inferior vena cava
diameter), biochemistry (such as brain natriuretic peptide),
electrophysiology (such as bioimpedance) and dynamic
intradialytic measurement (such as blood volume
monitoring). Many publications address one or more of
these methods, and several detailed reviews are available.
Some of these studies suffer from the limitations of
self-referencing design (demonstrating that the use of
method X to guide selection of target weight, reduces
the frequency of over-hydration as defined by method
X) and improvement in clinical outcomes are often
harder to demonstrate. For example, Leung studied
intradialytic hypotension in 32 haemodialysis patients
during 8 weeks of standard care and 8 weeks during
which ultrafiltration was informed by blood volume
monitoring, but no advantage was seen in terms of
hypotension frequency or symptoms [95].
No clear recommendation can be made regarding the
optimal method, but when clinical assessment feels
uncertain, it seems very reasonable to supplement this
with an objective measure, and bioimpedance has some
of the most promising data on clinically relevant
endpoints. In a randomised study of 156 patients, Nur
used bioimpedance data to adjust target weight in the
intervention group, whilst control patients had
bioimpedance measured but not available to treating
physicians [96]. Over the 12 month study, bioimpedance-
defined fluid overload was reduced in the intervention
group, as was blood pressure and left ventricular mass
index (131±36 to 116±29g/m2, p<0.001).
Regardless of the final volume achieved, the rate of
ultrafiltration appears separately to influence intra-
dialytic hypotension and clinical outcome. In a DOPPS
study of 22 000 patients in 7 countries, Saran observed
that an ultrafiltration rate over 10ml/h/kg was associated
with both intra-dialytic hypotension (RR 1.30, p=0.04)
and mortality (RR 1.09, p=0.02) [97]. And using data
from the HEMO study (N = 1846) Flythe divided pa-
tients according to ultrafiltration rate into three groups:
less than 10, 10-13, and over 13ml/h/kg, demonstrating
increased mortality in the highest ultrafiltration rate
group (HR 1.59, 95%CI 1.29-1.96) [98]. In the same
study, when treating ultrafiltration rate as a continuous
variable (using a cubic spline method) the authors iden-
tified 10ml/h/kg as the threshold beyond which mortal-
ity begins to increase, possibly quite sharply.
These studies are non-interventional, therefore associ-
ations are with observed (rather than prescribed) ultrafil-
tration rate, and there is also a close interaction with
session length (since rate is obviously the volume over
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the time) but these data provide a convincing argument
for avoidance of excessive rates. This should not how-
ever be at the expense of non-achievement of target
weight and acceptance of over-hydration (though staged
achievement over a number of sessions is frequently ap-
propriate) but rather should focus clinicians on session
length or addressing fluid gains between dialysis ses-
sions. The ultrafiltration required during dialysis de-
pends on the degree of over-hydration present at the
start of the session, so restricting fluid intake reduces
ultrafiltration rate, and is part of standard advice for the
majority of patients. Consideration must be given to the
cause of increased fluid intake such as habitual drinking
or thirst associated with either dietary sodium intake or
raised blood glucose. Advice on managing fluid intake is
therefore best delivered on an individualised basis, as
part of a dietary management plan to support adherence
and patient experience. This topic is covered in guide-
lines for the nutritional management of kidney disease.
Other relevant aspects of the dialysis prescription
include dialysate sodium and temperature.
Sodium balance, thirst and fluid control are also
influenced by dialysate sodium. Many observational studies
report lower fluid gains and lower blood pressure in
patients treated with low dialysate Na (typically 136-
138mmol/l). Antihypertensive treatment is frequently over-
looked in large studies, but reasonable supportive evidence
can also be found in interventional studies. For example,
Gumrukcuoglu reduced dialysate sodium from 140 to
137mmol/l in 41 patients over 6 months, reporting reduced
fluid gains, and no blood pressure change but a reduction
in antihypertensive use from 1.9 to 1.2 agents per patient
[99]. This potential benefit was not without drawbacks
however: in common with other groups, investigators also
found that cramps and intra-dialytic hypotension became
more frequent.
Lowering dialysate sodium therefore does appear to
improve fluid control and blood pressure, albeit with
some side effects, however another note of caution arises
from observations on mortality in different dialysate
sodium groups. Studying almost 30 000 patients from
DOPPS phases 1-4, with dialysate sodium varying be-
tween 138 and 142mmol/l in 90% of patients, Hecking
found that higher dialysate sodium was, as expected, as-
sociated with modestly increased fluid gain and systolic
blood pressure (increasing by 0.17% body weight and
0.66mmHg per 2mmol/l increase in dialysate sodium)
[100]. However, when addressing indication bias by
studying only the 56% of facilities using a standardised
dialysate sodium, they found that higher dialysate so-
dium was unexpectedly associated with reduced mortal-
ity (HR 0.88 per 2mmol/l increase in dialysate sodium,
95%CI 0.83-0.94). There is insufficient consistency in the
literature for a clear recommendation on dialysate
sodium, though if a standardised dialysate sodium is
used for all patients, some clinicians would avoid a
choice below 140mmol/l.
Dialysate temperature has been consistently associated
with intra-dialytic hypotension. Even thermoneutral
haemodialysis (temperature-matched so that the dialysis
circuit neither heats nor cools the patient) leads to an in-
crease in core temperature, though it is not clear if this is
due to reduced heat loss (for example due to cutaneous
vasoconstriction) or increased thermogenesis (for example
due to increased cardiac output) [101]. Reduced dialysate
temperature has therefore been the subject of a number of
interventional studies and two meta-analyses [102, 103].
In the most recent of these, Mustafa reported on 26
studies totalling 484 patients [103], observing an average
70 (95%CI 49 - 89) percent reduction in hypotension,
though with an increase in cold-related symptoms.
Twenty-four of these studies however were either small
(less than 20 patients) or of short duration (less than 3
sessions). The two largest studies provide further insight:
in Maggiore's study of 95 patients over 12 sessions
[104], isothermic (in which dialysate temperature is set
so that core temperature is unchanged) rather than
thermoneutral dialysis reduced hypotension from 50 to
25% of sessions. In Fine’s study of 128 patients over 10
sessions [105], 35'C dialysate rather than 37'C similarly
reduced hypotension, but the benefit was seen only in those
with subnormal temperature before dialysis. Preventing
temperature rise therefore appears to be more important
than cooling, which may be achieved on an individual basis
using dialysate 0.5 - 1.0 degree lower than core temperature
or in the whole unit by using dialysate temperature 36'C or
lower. The latter is probably adequate for most patients,
with individualisation seeming a reasonable option for
those with persisting hypotension or cold-related symp-
toms, and it is reasonably clear that if a standardised dialys-
ate temperature is being used, then the choice should be at
or under 36'C.
Regardless of the quality of dialysis prescription, intra-
dialytic hypotension will still occur, in some patients more
than others, for which prompt nursing intervention is es-
sential [106]. Common measures include leg raised posi-
tioning, ceasing ultrafiltration, and fluid administration
(saline being as good as albumin and far cheaper [107]).
Measures for “simple” intra-dialytic hypotension should be
coupled with assessment for underlying intercurrent illness
(such as infection or cardiac arrhythmia) or less commonly
a specific dialysis complication (such as air embolism or di-
alyser reaction). Frequent intervention should lead to re-
assessment of target weight / ultrafiltration setting and a
medication review - in some cases predialysis hypertension
may be preferable to dialysis intolerance. Specific pharma-
cological measures are rarely used but the alfa-agonist
Midodrine has reasonable supportive evidence: in meta-
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analysis the average improvement (increase) in systolic/dia-
stolic post-dialysis blood pressure was 12.4/7.7mmHg
[108].
Guideline 4.2 - Paediatric fluid considerations
In growing children we recommend clinical assessment
of fluid status and target weight, and dietetic assessment,
at least monthly. [1C]
We suggest supplementing clinical assessment with a
validated objective measure of fluid status such as
bioimpedance, on a monthly basis or more frequently
during periods of rapid growth or illness. [2C]
We recommend regular assessment of ultrafiltration
tolerance, using extended times to avoid excessive
ultrafiltration rates. [1D]
Rationale
Assessment of target weight in children and adolescents
is particularly challenging as it needs frequent
adjustment in line with growth or periods of illness. This
is particularly true for infants and adolescents during
rapid phases of growth. Overestimation of target weight
will result in chronic fluid overload leading to
hypertension and left ventricular hypertrophy, whereas
chronic under-hydration is likely to detrimentally affect
residual kidney function and lead to increased symptom-
atic hypotension both during and immediately post-
dialysis. Hypotensive tendency is also multifactorial and
cannot alone be relied on to ascertain a patient’s target
weight. It is therefore essential that target weight is ad-
justed at least on a monthly basis following clinical as-
sessment, in conjunction with dietetic review [109, 110].
Dialysate (Guidelines 5.1 – 5.4)
When the 2nd edition of the RA Guidelines was
published in 1997, the only recommendation relating to
the composition of the dialysate was that renal units
phase out the use of acetate in favour of bicarbonate
buffering, since the improved efficiency of dialysis could
overwhelm the capacity to metabolise acetate. The need
to keep bicarbonate separate from divalent cations to
prevent precipitation meant that dialysate had to be
produced using two different concentrates, leading to
the modern proportioning system in which sodium
bicarbonate is mixed with an electrolyte concentrate
(‘acid concentrate’) at the point of use, allowing
independent control of most dialysate constituents.
Some dialysate constituents have diversified whereas
others have gradually become standardized.
Dialysate calcium was often supra-physiological in the
1990’s (around 1.75mmol/L) to prevent hypocalcaemia,
but this became unnecessary with increasing use of vita-
min D analogues and calcium-containing phosphate
binders, so that dialysate calcium has become reasonably
standardized, usually in the range 1.25-1.50mmol/L.
Non-standard dialysate calcium may sometimes be help-
ful, for example in the context of calciphylaxis, but this
is usually driven by bone-mineral considerations and is
outside the scope of this guideline.
In the 1990’s, dialysate was usually glucose-free due to
cost and microbiological concerns, and hypoglycaemia
was often a problem for diabetic patients. Glucose con-
taining dialysate was initially prescribed for diabetic pa-
tients, but extended to all as costs improved, so that a
dialysate glucose of 5.5mmol/L is now standard in al-
most all UK dialysis units. The other constituent of dia-
lysis that has become standardised is magnesium, with
low (usually 0.25 or 0.375mmol/L) or high (usually
0.75mmol/L) magnesium being replaced by a dialysate
magnesium of 0.5mmol/L, close to the lower end of the
normal range.
Opposing these trends, there has been significant
diversification in dialysate potassium, and similarly,
buffer concentrations and practices vary between units
and manufacturers, and are discussed below.
Guideline 5.1 - Selection of dialysate potassium
We recommend an optimal pre-dialysis serum potas-
sium in the range 4.0–6.0mmol/L, remembering to con-
sider measurement errors (e.g. due to haemolysis) when
interpreting levels. [1B]
We suggest choosing dialysate potassium between 1.0
and 3.0mmol/L for the majority of patients, using an
individualised approach, in general using the highest
dialysate potassium that is sufficient to control pre-
dialysis hyperkalaemia. [2C]
We suggest a combined approach to managing
hyperkalaemia, which may include decreasing dialysate
potassium and/or other measures, including dietary advice,
medication review and increased dialysis frequency. [2D]
Rationale
Historically, it was often difficult to remove the
potassium accumulated between dialysis sessions, so
dialysate potassium between zero and 2mmol/L was
common. The requirement for dialysate with potassium
levels that are close to, or within, the normal range
reflects the increased efficiency of modern dialysis and
the increased age of the modern patient. In most units
dialysate potassium is determined by the choice of acid
concentrate: zero potassium is no longer used, and
suppliers offer concentrates with potassium between 1
and 4mmol/L.
Removal of accumulated potassium by intermittent
haemodialysis inevitably leads to a fluctuating profile of
serum potassium with a risk of cardiac arrhythmias at
both high and low concentrations. This probably
contributes to the clustering of sudden cardiac death
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around the peridialytic period, and at the end of the
weekend gap [111].
Both low and high pre-dialysis potassium are associ-
ated with increased mortality, so that the mortality curve
is U-shaped. Low potassium often appears more harmful
in unadjusted data: for example, in a study of 483 Tai-
wanese patients followed from 2004 to 2008, Hwang
showed that those with pre-dialysis potassium below
3.5mmol/L had more than twice the risk of mortality
than those with higher levels [112]. But this link may be
due to confounding by comorbidity malnutrition: in a
much larger study of 74219 patients between 2001 and
2004, a U-shaped risk curve was seen, with increased
mortality with pre-dialysis potassium outside the range
4.3–5.6mmol/L [113]. After adjustment for case mix and
malnutrition parameters however, the increased risk of
mortality remained only for the high potassium patients
(though the less than 4.0mmol/L category was not sub-
divided). The optimum pre-dialysis potassium therefore
appears to be above 4.0 with an upper limit between 5.6
and 6.0mmol/L, though the broader range seems more
appropriate given the considerations below.
The relationship between post-dialysis potassium and
mortality is unknown, as it is rarely measured, but the
risks of post-dialysis hypokalaemia can be inferred from
studies of dialysate potassium [114, 115]. For example,
Pun compared 502 patients who experienced sudden
cardiac arrest in dialysis units between 2002 and 2004,
with 1632 age and vintage matched controls, finding that
risk was doubled if the patient last dialysed with a low
dialysate potassium (less than 2.0mmol/L) [163].
The DOPPS review of modifiable practices associated
with sudden death included 36235 patients in 12
countries of whom 6606 were dialysed with dialysate
potassium at least 3.0mmol/L [116]. An increased risk of
sudden death was observed with dialysate potassium
below 3.0mmol/L (HR 1.17, 95%CI 1.01–1.37), though it
was not clear if this risk extended to those with pre-
dialysis serum potassium over 5.0mmol/L. Others have
suggested that lower dialysate potassium may prevent
sudden death in this subgroup [111, 113], but the latest
DOPPS analysis found no meaningful difference in mor-
tality or arrhythmia events between patients treated with
dialysate potassium of 2.0 or 3.0mmol/L [117].
The understandably strong impulse to control pre-
dialysis hyperkalaemia should therefore be tempered by
consideration of the less visible risk of post-dialysis
hypokalaemia. Pragmatically therefore one can conclude
the following general principles:
Firstly, pre-dialysis hyperkalaemia should be controlled,
though an overly tight range may be counterproductive, so
the previously recommended target for pre-dialysis potas-
sium still seems optimal (4.0 – 6.0mmol/L). Caveats to
interpreting this range should be noted: firstly, achievement
of pre-dialysis potassium within this range does not neces-
sarily mean that dialysate potassium is optimal, and sec-
ondly, consistent adherence to treatment is most likely just
as important as specifics of the potassium range or dialysis
prescription.
Secondly, non-dialysate approaches to hyperkalaemia
may sometimes be more favourable [118, 119]. Dietary
reduction may be preferable if it can be achieved without
an adverse effect on protein-calorie intake, and other
dialysis changes may be appropriate, such as increasing
blood flow, duration or frequency. Consideration could
also be given to potassium binding resins [120].
Thirdly, lower dialysate potassium does increase the
removal of potassium during each session [121], and
based on the risk of arrhythmias due to hyperkalaemia,
dialysate potassium should be reduced if other measures
are not possible or successful [122]. However, dialysate
potassium should be no lower than is necessary to
achieve this goal – individualization does therefore seem
necessary, so that each patient uses the highest dialysate
potassium which still controls pre-dialysis hyperkalae-
mia. This pragmatic approach has probably driven the
steady increase in the use of higher potassium dialysates,
and reduction in the use of concentrations below
2.0mmol/L, over the 5 DOPPS phases between 1996 and
2015 [117].
Finally, and particularly for measurements taken
remote from the laboratory, the relatively high frequency
of measurement errors (for example due to in vitro
haemolysis) should be remembered when interpreting
potassium levels.
Guideline 5.2 - Selection of dialysate buffer
We recommend an optimal pre-dialysis serum bicarbon-
ate in the range 18.0-26.0mmo/L, remembering to con-
sider measurement errors (e.g. due to exposure to air)
when interpreting levels. [1C]
We suggest the term ‘dialysate buffer’ rather than
‘dialysate bicarbonate’ to avoid confusion arising from
differences in manufacturers’ terminology. [2C]
We suggest choosing dialysate buffer below or equal
to 37.0mEq/L for the majority of patients, using a
standardised or individualised approach. [2C]
We suggest a combined approach to abnormal pre-
dialysis serum bicarbonate, which may include increas-
ing dialysis dose, oral bicarbonate, nutritional support,
or individualising dialysate buffer. [2D]
Rationale
We suggest a combined approach to abnormal pre-
dialysis serum bicarbonate, which may include increas-
ing dialysis dose, oral bicarbonate, nutritional support,
or individualising dialysate buffer. [2D]
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The literature on dialysate bicarbonate is difficult to
interpret due to unclear definitions when reporting the
bicarbonate and additional alkali components. Most
commonly the electrolyte concentrate contains a non-
bicarbonate acid, to reduce the deposition of calcium
and magnesium salts – acetic acid is perhaps the most
common, but citric acid and sodium diacetate may also
be used.
When mixed to form the dialysate, acetate reacts with
sodium bicarbonate to form sodium acetate, water and
carbon dioxide:
HC2H3O2 þNaHCO3→NaC2H3O2 þ H2Oþ CO2
The addition of 3mmol of acetic acid to a litre
solution containing 35mmol of bicarbonate therefore
reduces the bicarbonate concentration to 32mmol/L. In
publications, bicarbonate concentration in this dialysate
may variably be referred to as having a bicarbonate
concentration of 32 or 35mmol/L, with the acetate
content rarely reported.
In addition, the bicarbonate ‘setting’ on machines
from different manufacturers, refers variably to the
bicarbonate concentration either prior to (eg. Braun)
or after (eg. Fresenius) mixing with the electrolyte
concentrate. The terms ‘actual’ bicarbonate (because
that is what is actually added as sodium bicarbonate)
and ‘final’ bicarbonate (because that is the
bicarbonate in the dialysate at the point of use) are
sometimes used to separate their meaning. However,
the total buffer concentration remains the same
before and after this mixing, so this term has a clear
unambiguous meaning (equivalent to the sum of
bicarbonate and acetate concentrations in the final
dialysate). In a discussion of the DOPPS study of dialysate
bicarbonate, Tentori observed that when asked either for
the bicarbonate or total buffer concentration, most DOPPS
units returned the same figure, suggesting that clinicians
generally mean ‘actual’ rather than ‘final’ bicarbonate,
which is the same as total dialysate buffer [123–125].
The factors affecting pre-dialysis serum bicarbonate
levels include protein intake, residual kidney function,
interdialytic fluid gain, dialysate buffer concentration,
dialysis adequacy, oral sodium bicarbonate and other al-
kaline medications such as calcium carbonate [126].
Observational studies of pre-dialysis levels usually
show a J-shaped mortality curve, with most of the excess
risk associated with high levels of bicarbonate [127, 128],
but this appears to be due to the close link between high
bicarbonate and malnutrition. For example, in a study of
56385 between 2001 and 2003, Wu observed a progres-
sive increase in mortality as pre-dialysis bicarbonate in-
creased beyond 23mmol/L, but also strong associations
between higher bicarbonate and worsening markers of
nutrition including albumin, phosphate and protein in-
take [129]. When adjusted for comorbidity and 12 pa-
rameters associated with malnutrition, most of the
increased mortality appears with low bicarbonate, at
levels below 18–21mmol/L. Some guideline groups have
therefore increased the lower limit for optimal pre-
dialysis bicarbonate to 20 or 22mmol/L [130, 131].
Post-dialysis bicarbonate is rarely measured, but three
considerations argue for caution in attempting to
achieve a minimum pre-dialysis bicarbonate. Firstly, the
risks associated with abnormal bicarbonate are less clear
and of a lower magnitude than those associated with ab-
normal potassium (mortality hazard ratio of approxi-
mately 1.2 for the most extreme category of bicarbonate
versus 1.5 for potassium).
Secondly, although it is principally low bicarbonate
which carries risk, high pre-dialysis bicarbonate also ap-
pears to be harmful. Whilst much of the risk observed is
attenuated by adjustment, pre-dialysis bicarbonate is still
associated with increased mortality at levels above
27mmol/L [129]. Additionally, an increased risk of peri-
dialytic cardiac arrest has been observed with high pre-
dialysis bicarbonate: a Fresenius Medical Care memo in
2011 reported an internal case-control study of 941 pa-
tients in 667 facilities who suffered cardiac arrest in 2010.
Risk was 4.7 times higher in patients with pre-dialysis bi-
carbonate over 28mmol/L, and 6.3 times higher if they
also had pre-dialysis potassium below 4mmol/L [132].
Thirdly, high dialysate buffer is associated with increased
mortality. For example, in a large study of dialysate buffer
using DOPPS data (collected from 17031 dialysis patients
in 11 countries between 2002 and 2011) Tentori observed a
lower risk of mortality in patients treated with dialysate
buffer less than or equal to 32mmol/L, regardless of pre-
dialysis bicarbonate (HR 0.90, 95%CI 0.80–1.01) and higher
risk with dialysate buffer at or above 38mmol/L (HR 1.07,
95%CI 0.97–1.19) [123].
Pragmatically therefore one can conclude the
following general principles:
Firstly, pre-dialysis acidaemia should be controlled,
though an overly tight range may be counterproductive,
so the previously recommended lower target for pre-
dialysis bicarbonate still seems optimal, though the
upper target could safely be increased (18.0–26.0mmol/
L). As with potassium, achievement of this range does
not necessarily ensure optimal dialysis prescription.
Secondly, dialysate buffer at or over 38mmol/L should
generally be avoided, and the optimal dialysate buffer for
the majority of patients is probably in the region of 32–
35mmol/L.
Thirdly, many other factors affect pre-dialysis bicarbon-
ate, the dominant ones being nutritional state and dialysis
dose, so that abnormalities of pre-dialysis bicarbonate
should not lead clinicians automatically to think of
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adjusting dialysate buffer. High bicarbonate in particular
should prompt a nutritional thought process initially. It is
not clear that adjustment of dialysate buffer is a helpful
strategy for optimising pre-dialysis bicarbonate, or that
such an adjustment has much impact on pre-dialysis bi-
carbonate levels. Specific groups however, such as patients
with abnormal levels despite optimal diet and dialysis
strategy, may have something to gain from dialysate buffer
adjustment. Conversely, increased dialysate buffer may be
more hazardous in certain circumstances, such as in com-
bination with low potassium dialysate [122, 133].
Whilst it is a very reasonable thing to do, and might
prove to be beneficial in future studies, it is not
currently clear that individualization of dialysate buffer
is superior to standardization.
Finally, and particularly for measurements taken
remote from the laboratory, the relatively high
frequency of measurement errors (for example due
to carbon dioxide escape) should be remembered
when interpreting bicarbonate levels [134, 135].
Guideline 5.3 - Supplementation of dialysate with
phosphate
We suggest considering supplementation of the dialysate
with phosphate in patients on augmented dialysis
schedules. [2D]
Rationale
The conventional haemodialysis patient struggles to
achieve sufficient phosphate removal, and historically
dialysate has always been phosphate-free. Guidelines
usually focus more on the upper limit than the lower
limit for optimal pre-dialysis phosphate and ranges in
the region of 1.1-1.7mmol/L are often suggested, with
most of the emphasis on treatments to reduce phosphate
- indeed, most of the Renal Association's advice on
phosphate can be found in the guideline on mineral-
bone management. However, with demographic and
treatment trends of the last decade, low phosphate is
becoming more common, and since the symptoms of
hypophosphataemia are non-specific [136], this problem
may be easily overlooked.
The relationship between pre-dialysis phosphate and
mortality is J-shaped, with increased risk occurring at
both high and low levels. But phosphate is strongly asso-
ciated with age and nutritional state, so that the mortal-
ity risk associated with low phosphate is substantially
(although incompletely) attenuated by adjustment for
comorbidity and malnutrition [137]. In the context of
low pre-dialysis phosphate therefore, the main clinical
focus should be on nutritional assessment and support.
When patients are unable to consume sufficient
phosphate to match intradialytic loss, supplementation
of the dialysate is a logical approach to managing
hypophosphataemia. The argument for supplementation
is generally accepted in the context of augmented
dialysis, when post-dialysis phosphate is often measured,
and may be found to be very low in well-nourished pa-
tients [138]. It is common practice, for example, to sup-
plement dialysate with phosphate in pregnant patients
receiving daily dialysis.
Supplementation could also be used to prevent
undesired loss of phosphate in patients on conventional
regimes with low pre-dialysis phosphate that is refrac-
tory to other measures [139]. While this does appear to
be clinically helpful in case reports, data to support this
approach remain limited. However, as patients with low
pre-dialysis phosphate currently receive a form of dialy-
sis which inevitably worsens this abnormality, so the in-
stinct to ‘do no harm’ may be a sufficiently persuasive
argument for some clinicians.
Phosphate precipitates in solutions containing
calcium or magnesium, so like bicarbonate, must be
added to the electrolyte concentrate at the point of
use, but there is currently no commercially available
phosphate additive approved for use in intermittent
haemodialysis [140, 141]. ‘In house’ supplementation
can be achieved by adding phosphate salts to the
electrolyte concentrate at the start of the session, but
solutions intended for intravenous use typically
contain potassium and are too dilute. Pharmaceutical
grade phosphate salts in powder form can be used,
but require quality assurance on storing, weighing,
adding and ensuring complete dissolution. The most
common method is therefore ‘off label’ use of
solutions intended as enemas: Cleen (formerly Fleet)
Enema for example, is very suitable for enriching
dialysate [142], although it contains antimicrobial
preservatives (benzalkonium chloride and disodium
edetate) which are widely used in medical products
such as eye drops, which might have adverse effects
in this context. The use of Cleen Enema in dialysate
has a good safety record however: Pierratos first
reported its use in nocturnal dialysis in the late 1990s
[143], and frequent dialysis programmes in many
countries have adopted this method [144, 145].
Practical advice on adding phosphate to dialysate is
provided in Appendix 4.
Guideline 5.4 - Paediatric dialysate considerations
We recommend individualisation of dialysate electrolyte
concentrations, including potassium, buffer and calcium.
[1C]
We suggest an individualised dialysate temperature,
between core temperature and 0.5°C below, with
monitoring of intradialytic core temperature for
neonates and smaller children. [2D]
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Rationale
Adult guidelines for dialysate composition (sections 5.1
– 5.3) are generally applicable to children, though there
are a number of additional considerations.
In children with residual kidney function, tubular
dysfunction is not uncommon, leading to electrolyte
wasting and hypokalaemia or acidosis. Calcium balance
is also more complex in children: the normal range for
calcium is age-dependent and growing children require
a positive calcium balance, so that hypocalcaemia may
be both more common and more harmful, and yet vas-
cular calcification is sometimes seen even in children
and adolescents, in whom calcium-phosphate product is
an important risk factor [146, 147]. Similarly, dietary
protein intake is often proportionately greater than that
of adults, and pre-dialysis acidosis therefore more com-
mon. The complexity and clinical heterogeneity of these
issues therefore argues strongly for a more individualized
approach to dialysate composition in children [148].
Thermal exchanges during dialysis may also be more
significant particularly in neonates and younger children,
due to the proportionately greater blood flow, and
sometimes a reduced capacity for compensation due to
body size. Hypothermia should therefore be avoided by
individualising dialysate temperature, with intradialytic
monitoring in those most at risk. Control of thermal
exchanges is available on some modern dialysis
machines.
Anticoagulation
We recommend that patients without increased bleeding
risk should be given unfractionated or low-molecular-
weight heparin during dialysis to reduce clotting of the
extracorporeal system. [1A]
We recommend that systemic anticoagulation should
be omitted or minimised in patients with increased
bleeding risk. [1C]
We recommend that patients with heparin allergies
should be prescribed a non-heparin form of anticoagula-
tion. [1A]
Rationale
Platelet activation in the extracorporeal circuit accelerates
thrombin generation via the intrinsic coagulation
pathway, so that anticoagulation is usually required to
prevent thrombosis. Unfractionated heparin is used as the
standard anticoagulant worldwide in view of its proven
efficacy, ease of use and long safety record unless the
patient has recent or active bleeding, thrombocytopenia,
heparin allergy or heparin induced thrombocytopenia.
With a mean half-life of 1.5 hours, heparin is usually ad-
ministered as a loading dose of 1000-2000 IU followed by
a continuous infusion of 500-1500U/h that is discontinued
approximately 30 minutes before the end of the dialysis
session. Monitoring can be performed by measuring the
activated partial thromboplastin time ratio (aPTTr) or the
whole-blood activated clotting time aiming for around
150% of pre-dialysis or centre normal values [149, 150].
But in practice the bolus dose, infusion rate and stopping
times are adjusted empirically, according to clot formation
in the dialysis circuit, and the time for needle sites to stop
bleeding. Heparin dose may need to be increased with
higher haematocrit, or reduced / withdrawn in patients at
risk of haemorrhage, those with thrombocytopenia or on
long term anticoagulation [151].
Alternatively, a low molecular weight heparin may be
used [152], having a longer half-life, given as a single ‘ar-
terial limb’ bolus at the start of dialysis [153]. Although
monitoring can be performed using anti-Xa activity,
these are not always available and laboratory testing cor-
relates less directly with clinical effect, so as with unfrac-
tionated heparin, dose adjustment is usually empirical,
but larger or repeated doses may be needed depending
on convective clearance and session length, and reduced
doses for those at risk of haemorrhage [154]. Several sys-
tematic reviews comparing low-molecular-weight with
unfractionated heparin have found no difference in the
incidence of bleeding complications, post-dialysis access
bleeding, or thrombosis of the extracorporeal circuit
[155–158]. With its convenience for nursing staff, the
use of low-molecular-weight heparin is becoming more
common in Europe.
For patients at increased risk of bleeding, several
options are used in clinical practice. Firstly, several
techniques require no anticoagulation to be administered
during dialysis, including: combining a high blood flow
rate and regular pre-dialyzer circuit flushing every 15-30
minutes [159, 160]; using a heparin coated dialyzer [161,
162]; adding heparin to the rinsing solution [160]; or using
a dialysate containing citrate [163–165].
Secondly, a regional anticoagulant can be used such as
citrate, prostacyclin (epoprostenol) or nafamostat (not
currently available in UK). Regional anticoagulation with
citrate [166] and epoprostenolol [167] have both been
reported to reduce the risk of haemorrhage compared to
heparin, though there are drawbacks: epoprostenol may
induce hypotension and is costly, whereas citrate
administration requires re-infusion of calcium based on
electrolyte monitoring, adding complexity and nursing
staff time [168]. Finally, lower doses of unfractionated or
low-molecular-weight heparin have been used with cau-
tion in patients at risk of bleeding [151, 154].
Heparin induced thrombocytopenia, usually occurring
shortly after regular exposure to heparin, and sometimes
with thrombosis, may occur in heparin-treated dialysis
patients [169, 170]. The risk of heparin induced
thrombocytopenia can be estimated using the 4T scoring
system [171], and is usually confirmed by laboratory testing
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and detailed guidelines on diagnosis and treatment are pub-
lished by the British Society of Haematology, but in sus-
pected or confirmed cases, all heparins should be withdrawn
[172]. The risk of thrombosis increases with the severity of
thrombocytopaenia, and anticoagulation is usually started
with either the direct thrombin inhibitor argatroban [173],
or a natural (danaparoid) or synthetic (fondaparinux) hepari-
noid [174, 175]. Argatroban is reversible, given by continu-
ous infusion, and requires careful laboratory monitoring
with aPTTr. The heparinoids are renally excreted and have
prolonged half-lives in dialysis patients, such that monitor-
ing of the bolus given with a dialysis session can be based
on anti-Xa activity prior to the following session. Once the
platelet count returns to normal, patients are usually antic-
oagulated with warfarin, but in the majority of cases anti-
bodies disappear with time, and patients have been
successfully re-challenged with unfractionated and low-
molecular-weight heparins once laboratory testing becomes
negative [176].
Adverse events during dialysis (Guidelines 7.1 – 7.3)
Guideline 7.1 - Routine blood loss
We suggest that during washback, dialysis lines and
dialyser are observed to ensure residual blood loss is
kept to a minimum. [2C]
Rationale
A small amount of blood loss occurs during normal
haemodialysis, for example due to blood retained in the
dialyser and circuit after washback, and bleeding into
the dressing over needling sites, but there is no clear
consensus as to what constitutes a ‘normal’ quantity of
blood loss due to dialysis. The literature on minimising
blood loss during haemodialysis is sparse, and much of
the evidence is of limited quality.
The weighed gauze method has been to quantify
bleeding after removal of needles, with ‘excessive’ defined
as blood-soaked gauze weighing over 4g [177]. And exces-
sive bleeding has been associated with poor outcomes, for
example in a study of 4152 dialysis sessions in 143 pa-
tients, Lin found that excessive bleeding following dialysis
needle removal occurred regularly, and was associated
with lower haemoglobin levels [178, 179]. Kalantar-Zadeh
suggested patients can lose up to 3g iron per year, with
one gram being lost in the lines and dialyser, and a further
gram lost in blood sampling [180]. Though it is unclear
how they are derived, these estimates suggest that up to
20ml per session may be normal.
In a comparison of buttonhole versus rope-ladder can-
nulation in 33 patients, Verhallen found no difference in
bleeding times after needle removal between the two
techniques [181]. Various suggestions have been made,
for example McCann suggested needling at an angle of
25 degrees [182], and Fruits suggested flushing the
arterial dialysis needle with saline, and reducing the
amount of blood drawn for testing, but none of these
measures is well supported by clinical evidence [183].
Currently there is insufficient evidence therefore to sup-
port any recommendations regarding blood preservation
and management of vascular access.
Clotting of the dialysis circuit leads to much greater blood
loss than is routine. Adequate but safe anticoagulation is an
important component of prevention, and is covered
elsewhere in this guideline, but regular monitoring during
dialysis and observation of the colour of the lines and
dialyser post-dialysis, also play a role. This concept is sup-
ported in literature, for example Kalocheritis noted the con-
tribution of this type of blood loss to anaemia, and the
relevance of human factors [184]. Reasonable consensus
therefore supports the importance of nursing observation,
particularly during washback.
No evidence was found regarding the effects of
excessive blood sampling on blood loss. Daugirdas and
Tattersall point out that on-line measurement of ad-
equacy may reduce the need for blood sampling, but de-
scribe the benefits mainly in respect of cost and staff
time [185]. However, ensuring that blood samples are
taken only when required for routine monitoring or for
additional diagnostic indications, is perhaps obvious
common sense.
Guideline 7.2 - Disconnection haemorrhage
We recommend maintaining awareness of the risk of
disconnection, the limitations of pressure alarms, and
importance of direct observation, through a program of
education, including patients and carers. [1D]
We suggest regular assessment of individual risk, so
that high risk patients can have enhanced monitoring,
which could include specific devices. [2B]
Rationale
Disconnection leading to haemorrhage may occur at any
part of the dialysis circuit, though venous needle
dislodgement may be the most frequent and serious,
with rapid blood loss occuring at the rate of the blood
flow pump, until it is detected. Disconnection incidents
are thought to be uncommon, but the true prevalence is
uncertain due to inconsistent reporting. Once detected,
management begins with haemostasis and fluid
resuscitation, as with any major haemorrhage, and the
literature concentrates instead on methods to minimise
risk and enhance detection, with publications available
from the EDTNA/ERCA and the American Nephrology
Nurses Association [186, 187].
Variability in human processes is recognised as an
important factor, and most units have established protocols
to ensure consistency in aspects of care such as taping
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needles in position to minimise the chance of
disconnection [188].
Dialysis machines have several types of safety monitor
[189] and if disconnection does occur, the drop in
pressure should be detected and cause the machine to
alarm. However, it has been repeatedly demonstrated
that these alarms cannot be relied on to detect all cases
[190]. The use of asymmetric windows (such as -30 to
+70mmHg) may be helpful to maximise the detection of
disconnection, while minimising alarms from increases
in pressure at the venous needle [191, 192].
Because machine alarms cannot be relied on, direct
observation remains important, involving vigilance on the
part of nursing staff, and unit management, so that lines
of sight are not obscured, patients are not dialysing alone
and their vascular access sites are not covered. Because of
the low prevalence of disconnection, complacency may
develop: continuous education is therefore advocated to
ensure awareness amongst healthcare staff, patients and
their carers [193].
Risk of disconnection is greater in some patients, and
enhanced monitoring may be appropriate based on
individual risk assessment. Simply placing patients closer
to the nursing desk may be sufficient, but reliable
monitoring can also be achieved by use of blood loss
detection devices, which typically are secured at the site
of vascular access and alarm on the detection of blood
[194, 195]. Device monitoring may be appropriate for
patients at high risk, such as confused or agitated patients,
and may have a greater role in home haemodialysis
programmes [196–199]. One interventional study
considered the effect of blood loss detection devices on
nursing staff, showing an improvement in self-reported
feeling of safety when devices were used [200].
Guideline 7.3 - Immune reactions during dialysis
We recommend that dialysis staff should be aware of the
features and management of dialysis reactions, and
should have access to a range of dialyser types. [1C]
Rationale
From the early 1980s reports appeared describing abrupt
clinical reactions occurring soon after the onset of
dialysis [201]. These have traditionally been classified
into two types.
Type A reactions were said to affect less than 1% of
patients per year, often re-occurring in the same patient,
with onset within the first few minutes of dialysis.
Mainly occurring with first use, rather than re-used dia-
lysers the features were quite ‘anaphylactic’ in nature
(itching, flushing, bronchospasm, hypotension, some-
times with burning at the access site) and often severe,
with cardiac arrest occasionally described [202]. Associ-
ated with eosinophilia, these reactions were caused
mainly by residual ethylene dioxide (used to sterilize
membranes) with antibodies detectable in many cases
[203]. Similar reactions were described to polyacryloni-
trile membranes, especially in ACE inhibitor treated pa-
tients (by increasing kinin activation) and in hydrogen
peroxide treated re-used membranes [204]. Immediate
cessation of dialysis was usually necessary, along with
anaphylaxis-type treatment. Extra rinsing or a change of
membrane sterilisation would often prevent
reoccurrence.
Type B reactions, said to be more common, occurring
later in the dialysis session, were typically less severe,
improving with continued dialysis. Characterised mainly
by chest and back pain (also sometimes with vomiting,
breathlessness and hypotension) they were caused by
complement activation and pulmonary cell
sequestration, and associated with transient reductions
in circulating white cells. These reactions were clearly
linked with the ‘bio-incompatibility’ of cellulose-based
membranes [205].
Dialyser re-use, ethylene dioxide sterilisation and un-
modified cellulose membranes are all now very uncom-
mon, and as dialysis practices have evolved, the
epidemiology of these reactions has changed, reflected in
the changing literature (Fig. 2). In modern practice dialy-
sis reactions are uncommon but do still occur, including
polysulphone allergy, heparin allergy and isolated
thrombocytopenia.
Reactions with ‘type A’ (anaphylactic) features continue to
occur with polysulphone membranes, though many variants
are described, including those with fever as the predominant
symptom [206]. Eosinophilia is an important clue, though
not invariably present, and other blood tests (tryptase, total
IgE) may be useful [207]. The diagnostic hallmark is
resolution of the syndrome following a change of membrane
type, and (though little guidance is available from literature)
anaphylaxis treatments are often given, with steroid pre-
treatment sometimes used before dialysis sessions. Stopping
ACE inhibitors may also reduce the severity.
Reactions to intra-dialytic heparin are sometimes de-
scribed, ranging in severity from asymptomatic to a
serotonin-like syndrome of breathlessness and flushing,
often with hypertension. These are usually but not al-
ways associated with thrombocytopenia (persisting be-
tween dialysis sessions) and thrombotic complications
may occur. Transient asymptomatic thrombocytopenia
has also been described, often recovering between dialy-
sis sessions so that pre-dialysis platelet count may be
normal. This reaction has been associated with electron
beam membrane sterilization, but the mechanism is un-
known [208].
Several complications other than dialyser reactions
may present with similar peri-dialytic symptoms. More
common ones include bacteraemia and hypovolaemia,
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whilst disequilibrium, air embolism and the chloramine
/ hard water syndromes are rarer. Water purification
complications may be more common in the home
haemodialysis setting.
Patient experience of dialysis (Guidelines 8.1 – 8.4)
Guideline 8.1 - Home haemodialysis
We recommend that home haemodialysis should be
available in all units as part of a comprehensive renal
replacement therapy programme. [1A]
We suggest training patients and/or care partners to
achieve a defined set of competencies, using an
individualised approach to training method and speed. [2D]
We suggest units form a contract with patients
outlining responsibilities, including an agreement to
dialyse as per prescription and trained technique, and
including a policy for re-imbursement of directly arising
patient costs. [2D]
We suggest supporting patients with a specific team
including nephrologists, technicians, and nurses, with
rapid access to dialysis in-centre when required. [2C]
We suggest an agreed individualised prescription for
home haemodialysis, taking into account lifestyle goals,
with the same dose and time target considerations as
centre-based patients. [2C]
We recommend enhanced safety measures for patients
who dialyse alone or overnight, and an enhanced risk
assessment for patients with blood-borne viruses. [1C]
Rationale
There is increasing evidence of the benefits of augmented
haemodialysis schedules, in terms of both outcome and
health-related quality of life, but providing more frequent
dialysis in-centre is a challenge in the UK, and it is widely
recognised that augmented schedules are most easily
accommodated in the home setting [33, 35, 209–212].
The literature on home haemodialysis and augmented
schedules therefore overlaps substantially, but home
haemodialysis additionally is increasingly
acknowledged to provide a level of convenience and
flexibility not achievable in-centre.
Despite these benefits the penetration of home
haemodialysis in the UK remains low, comprising only
0.4% of incident and 2% of prevalent dialysis patients.
Many organisations such as NICE and KDIGO promote
universal availability for clinically suitable patients,
acknowledging that collaborative working between centres
maybe required [213, 214]. But it is clear from registry
data that variability of access still exists, with some centres
not offering this modality, and considerable variation in
uptake between centres.
Home haemodialysis patients must be able to manage
their dialysis safely, and monitor their condition. Modality
decisions should be supported by a full assessment of
clinical and social circumstances, as well as the home
environment, including a discussion of the impact of
therapy on others within the household [215]. It is
essential that patient and carer expectations and fears are
appropriately addressed before commencing training
[217]. Few data are available to guidance on clinical
suitability, but the ability to complete training may be
more important than clinical diagnosis: a number of
programmes have reported that patients with complex
comorbidities can improve with more frequent therapy,
more tailored to their needs [222, 223].
Training on a ‘1 to 1’ basis with a specific training
staff is widely accepted as optimal, with the learning
style and training duration adapted to the individual
[221]. Type of vascular access should not be a
limiting factor, but appropriate training, surveillance
Fig. 2 Literature timeline showing the changing epidemiology of dialysis reactions
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and technique assessment form essential parts of the
home haemodialysis programme [224, 225].
The success of a home haemodialysis programme is
dependent upon a skilled and specific multi-disciplinary
team facilitating education, training and patient support
in the community, and optimal individual outcomes are
dependent on patient understanding, and appropriate
cooperative liaison with this support [218]. This may be
facilitated with an explicit contract, so that the manner
in which this clinical responsibility is shared is clear.
The financial responsibility for treatment rests with the
provider, and re-imbursement of directly arising patient
costs should be readily available [216].
A home haemodialysis Programme requires adequate
medical, nursing and technical support, and should
support at least 12 to 20 patients, and train at least 10
patients per year in order to maintain appropriate staff
expertise and cost effectiveness, so smaller renal units
may find it more appropriate to share resources with
other centres. Minimum safe staff to patient ratios are
not well defined, but recommendations for peritoneal
dialysis (such as minimum of 1 nurse per 20 patients)
may be relevant [218–220]. However, as training for
home haemodialysis is more complex, additional staffing
should be considered to ensure that training new
patients does not detract from the support of established
patients [217]. Patient mix should also be considered, so
that programmes with a greater number of complex
patients are staffed more favourably [224, 226].
Home haemodialysis patients should receive the same
level of medical supervision, and the same monitoring
and dose considerations as in-centre patients, and as for
other patients, the schedule should be individualised de-
pending on patient values and therapeutic goals. Dialysis
dose should be quantified as for other augmented sched-
ules, but should be interpreted with the flexibility of the
patient’s schedule also in mind. To ensure that the home
dialysis team can provide the best possible support that
is responsive to the individual, recording of sessional de-
tails by the patient or carer is desirable [229].
Specific circumstances may require additional risk
assessments and/or additional measures: enhanced safety
measures, for example to detect disconnection, should be
available for patients dialysing alone or overnight, and
protection of household contacts of patients with blood-
borne viruses should be considered, particularly for those
directly involved in therapy [187, 224, 227, 228].
Guideline 8.2 - Shared haemodialysis care
We suggest that all centre-based haemodialysis patients
should have opportunity and encouragement to learn as-
pects of their dialysis treatment, and take an active role
in their care. [2D]
Rationale
There is little research that has been directly conducted
into shared haemodialysis care, however there is
considerable evidence of the benefits of supported self-
care in other long term conditions [230]. Low health lit-
eracy amongst dialysis patients is associated with worse
survival [231] whereas self-motivation and education can
result in better care, for example, in phosphate control
and fluid balance [232, 233]. As with the broader NHS,
dialysis services are experiencing considerable pressure
to deliver high quality in the face of fiscal challenge, and
an important mechanism to ensure that quality of care
is maintained, is to engage service users as true partners
in their own treatment: self-management is an ambition
in ‘Kidney Health: Delivering Excellence’ [234]. To
achieve this, health care professionals need to enhance
their roles, becoming educators and facilitators, support-
ing patients to take a greater role in their own care, and
increasing their opportunities for dialysing at home.
Shared haemodialysis care impacts on all domains of
health. Central among these are: the enhanced patient
safety that comes from education on infection control
(see the WHO campaign ‘Save lives: clean your hands’
[235]); the enhanced equity consequent on offering all
patients training in their treatment rather than only
those planning haemodialysis at home; and the
enhanced experience when patients can put themselves
onto dialysis, or manage their own alarms, without
waiting for a nurse [236].
The process of haemodialysis can be broken down into
approximately 14 tasks (Appendix 5). The exact
arrangements may vary between units but the concept is
essentially the same: that centre-based patients are given
the opportunity to train to perform one or more of these
tasks. It is key that patient involvement is voluntary, and
that learning is individualised to the style and speed of the
individual. Shared haemodialysis care is associated with a
range of barriers and enablers that are best explored
through quality improvement work, in order to design
favourable conditions for successful implementation.
Guideline 8.3 - Intradialytic exercise
We recommend that intradialytic exercise should be
available in all units, as a treatment for enhancing physical
functioning, in patients without contraindications. [1B]
We suggest that intradialytic exercise be considered as
a method of enhancing quality of life. [2C]
We suggest that exercise regimes be devised by
appropriately trained staff. [2C]
Rationale
Whilst cardiovascular disease remains the principal
causes of death in dialysis patients [237], there is a
significant interaction with body composition, with
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muscle wasting in particular exacerbating mortality
[238]. Muscle wasting and poor physical fitness also
reduce functional abilities including activities of daily
living, thus reducing quality of life in haemodialysis
patients [254]. However, muscle wasting is modifiable by
exercise, and epidemiological studies suggest that regular
exercise can even reduce mortality [239], but
unfortunately daily physical activity is typically low in
haemodialysis patients, perhaps due to the time burden
and symptoms associated with treatment [240].
Based on evidence from eight systematic reviews and
meta-analyses [241–248], analysing data from 1000 adult
participants on dialysis, the clinical effectiveness of exer-
cise on physical function and health related quality of
life can be summarised as follows:
1) Despite the high-risk status of dialysis patients, no
serious exercise-related adverse events have been
reported from over 30 000 patient-hours of exercise
observed [244, 246]. Adverse events reported in-
clude post-exercise hypotension, fatigue, myalgias,
painful feet, and aggravation of foot ulcers, though
not with increased incidence in exercise groups.
Compliance with exercise programmes ranged from
43 to 100%, and dropout rates from 15 to 50%.
2) Short term (2-6 months) prescribed exercise of any
type, frequency and intensity, resulted in significant
and clinically moderate/large improvement in
cardiorespiratory fitness, with a mean increase in
peak VO2 of 5ml/kg/min [243, 246].
3) Any prescribed exercise delivered during
hemodialysis sessions produced significant and
clinically moderate improvement in muscle strength
[245], with a mean increase of 9.9kg [243].
4) Any type of prescribed exercise consistently
produced significant and clinically large
improvements in some indices of functional
capacity, such as ‘sit to stand’ transfers [247],
whereas other indices, such as walking
performance, were improved according to some
reviews [247] but not others [243, 245].
5) Self-reported physical function was significantly
improved in exercising patients [247]. This often
contributes to quality of life scores, and may
therefore explain why some studies conclude that
exercise improved quality of life.
Taken together there is therefore good evidence that
the uptake of regular exercise improves physical
function and quality of life in haemodialysis patients,
without causing significant harm, and that delivery of
exercise within haemodialysis sessions can achieve this.
Exercise during the dialysis process may also assist with
solute clearance. Enhanced urea clearance is predicted by
modelling but an impact on Kt/V is found in some studies
(nine of eighteen studies reviewed) but not others [249],
whereas improvements in phosphate clearance and serum
levels are consistently observed [249–253].
Some evidence suggests the type of exercise most likely to
be beneficial: larger improvements were observed with
interventions delivering a progressively increasing exercise
volume, at least three times per week, for at least 30
minutes, lasting for at least four months, and including an
additional resistance-training component [244, 246–248].
Comparative evidence for specific exercise programmes is
currently unavailable, but some guidance on practical imple-
mentation of intradialytic exercise is offered in Appendix 6.
Guideline 8.4 - Dialysis experience for children and
adolescents
We recommend that haemodialysis for children and
adolescents should be delivered in a dedicated paediatric
dialysis centre or at home, with the involvement of a
paediatric multidisciplinary team. [1C]
We recommend that adolescents should commence an
active transition programme by 14 years, or at the time
of presentation in those already over 14. [1D]
Rationale
Haemodialysis sessions are associated with physical
symptoms, social restriction, and loss of control, which
for children and adolescents may be particularly
depersonalising and unpleasant. These effects may be
mitigated by an appropriate environment and trained
support staff, and in-centre dialysis is therefore best de-
livered in a dedicated unit, with paediatric nephrologists
working alongside the full multidisciplinary team, in-
cluding nurses, dietitians, psychologists, play therapists,
teachers and social workers [148, 255, 256]. In this way
children can be supported to reach their full potential
despite the burdens of treatment. The first dialysis ses-
sion is of particular importance in establishing thera-
peutic trust and parental confidence - psychological
preparation for this event can alleviate anxiety, reduce
symptoms and improve the tolerability of dialysis.
Children and adolescents can be supported to take on
aspects of their own care, often along with parents or
guardians, and are likely to gain as much benefit as
adults from involvement in a shared care program [257].
And home haemodialysis has many advantages for
children, allowing an augmented schedule without
institutionalisation, and providing a flexibility which can
reduce the impact of dialysis on social development.
Transition describes the process of preparing
adolescents, along with their families, for the move from
paediatric to adult care. It should be individualised,
taking into consideration the physical and psychological
development of the adolescent, and requires a variable
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amount of time [258]. Adolescents will suffer the least
disruption if moved to adult care following engagement
with a transition programme, and should be introduced
to the concept of transition in early adolescence (12-14
years). For those over 14 when presenting to paediatric
services, transition planning should commence immediately
alongside other aspects of care.
Appendix 1
Simplified mathematics of urea clearance
Urea Kinetic Modelling and Kt/V
In the design of the NCDS study, ‘dose’ of dialysis was
defined as a target for time-averaged urea (low urea =
high dose group). However, urea level in dialysed pa-
tients depends as much on protein intake as the amount
of dialysis: loss of appetite may lead to low urea, so this
cannot be relied on to indicate sufficient dialysis. The
concept of Kt/V emerged from this study, where K is di-
alyser clearance (of urea), t is treatment time and V is
volume of distribution (of urea). Despite its appearance,
Kt/V is not intended as something to calculate from its
constituents K, t and V, since only t is accurately known,
but by consideration of the following relationship: the
rate of removal of urea is proportional to its concentra-
tion. Following this basic rule, the concentration of urea
after a dialysis session of duration t, is therefore approxi-
mated by:
Upost ¼ Upre x e^ −Kt=Vð Þ
where
Upost ¼ urea post dialysis
Upre ¼ urea pre dialysis
Kt/V is therefore the negative exponent in a numerical
model describing the fall in urea during a single dialysis
session. Different forms of Kt/V reflect models with
differing levels of complexity, which in addition to the
concept above, may also take account of other aspects
such as: urea removal by convection, urea generation,
and separate “pools” within which urea is distributed.
The gold standard Kt/V is derived from ‘Urea Kinetic
Modelling’: iterative computation to give the best fitting
coefficients for urea clearance and generation, based on
three urea measurements (spanning an interdialytic
interval and a dialysis session). This approach is broadly
accepted, but although online programs are available
(e.g. Solute Solver, www.ureakinetics.org) the non-
formula method hinders widespread use, and a number
of simplified approaches are more common - three are
commonly used and summarised here.
Log-Ratio and Urea Reduction Ratio
If the basic model above is used, ignoring other
factors, with urea assumed to be distributed evenly in
body water, then Kt/V is given by the log ratio:
Kt=V ¼ − loge Upost=Upre
 
This simple form of Kt/V, sometimes called the “Log-
Ratio”, is mathematically related to the Urea Reduction
Ratio (URR), the reduction in urea as a ratio of the pre-
dialysis level, often expressed as a percentage:
URR 100 x Upre−Upost
 
=Upre
Kt=V ¼ loge 100= 100−URRð Þ½ 
A threshold for URR is therefore precisely the same as
a threshold for Kt/V calculated by the Log-Ratio.
URR is the simplest measure of dialysis dose, and is the
current audit measure collected by the Renal Registry.
URR has the disadvantage that it does not account for
clearance due to ultrafiltration, urea generation or urea
rebound. It tends to over-estimate dialysis dose in shorter
treatments, and under-estimate dose in treatments longer
than 4 hours. However, it is long established and there is
no argument over its calculation.
Single-pool Kt/V (spKt/V)
Although the above is technically also a single-pool
method, the term ‘single pool Kt/V’ usually refers to the
method proposed by Daugirdas, which calculates Kt/V
by a formula taking account of the effect of
ultrafiltration:
spKt=V ¼ − loge Upost=Upre
 
− t=7500ð Þ
 
þ ½ UF=TWð Þð4− 3:5 Upost=Upre
  

where
t ¼ dialysis time minð Þ
UF ¼ ultrafiltration litresð Þ
TW ¼ target weight kgð Þ
This method takes account of more factors but
consistently over-estimates Kt/V. Targets have therefore
often been expressed with an adjustment factor if using
spKt/V (eg. “eKt/V = 1.2, or spKt/V = 1.4”).
Equilibrated Kt/V (eKt/V)
The dynamic interaction between urea concentrations
in intra- and extra-cellular pools, results in reduced ef-
fectiveness of treatment because dialysis removes urea
only from the extracellular pool, which is then refilled
from the intracellular pool during and after dialysis. This
results in a gradual rebound in urea concentration for
approximately one hour after dialysis, so that if post-
dialysis urea is measured immediately, then the treat-
ment effect is over-estimated.
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Equilibrated Kt/V attempts to correct for this by using
a post-rebound urea measurement:
eKt=V ¼ − loge Upost−rebound=Upre
 
Due to the inconvenience of measuring urea post-
rebound (an hour after dialysis has finished) a formula is
used to adjust for this reasonably predictable effect using
urea measured immediately. More than one equation
has been published but there is very little difference be-
tween them. This one is known as the Tattersall version:
eKt=V ¼ spKt=Vtð Þ= tþ 35ð Þ
Apparent urea rebound is dependent on vascular
access, so 35 is replaced by 22 in patients dialysing via a
catheter. This method is non-biased and has most often
been used in studies of dialysis dose, such as the HEMO
study. Targets given in terms of other measures of dialy-
sis dose such as URR may be useful in comparing units,
but are not accurate for individual patients.
All forms of Kt/V (including eKt/V) implicitly use V to
normalise for body size, whereas body surface area is
conventionally used to normalise renal function. There
are theoretical reasons to believe that normalisation of
Kt/V to other body size parameters such as body surface
area would be more useful, but these concepts have not
gained widespread acceptance.
The Log-Ratio is a reasonable approximation of eKt/V
since the underestimation (from ignoring ultrafiltration
and urea generation) is offset by overestimation (from
ignoring urea rebound). In fact, for a 4 hour session,
with UF/TW = 0.02, in a fistula patient, the Log-Ratio is
almost identical to eKt/V, with URR = 70 being equiva-
lent to eKt/V = 1.2. However, in most other settings,
Log-Ratio will underestimate or overestimate dose, so
that the target URR required to achieve eKt/V = 1.2
needs to be varied, as in this table:
Urea Reduction Ratio equivalent to eKt/V = 1.2
Time (h) by access type UF/TW
Fistula Catheter 0.02 0.03 0.04
3.5 71.0 70.2 69.4
4.0 70.0 69.2 68.4
4.5 3.5 69.1 68.3 67.5
5.0 4.0 68.2 67.4 66.6
4.5 67.4 66.6 65.8
5.0 66.8 66.0 65.2
Appendix 2
Adjusting dialysis for residual function
Since residual renal clearance (Kru) is continuous, and
dialysis clearance is intermittent (with Kt/V referring to
clearance during a single dialysis session), the quantities
of both cannot simply be added. When it is planned to
reduce dialysis dose by incorporating the contribution of
residual function, it is necessary to somehow add these
clearances so that the dialysis component is appropriate.
Three methods of combining these clearances have been
proposed.
Converting Kru to an equivalent eKt/V (Combined
eKt/V)
In this method, residual kidney function is converted
to an equivalent per-session eKt/V, by multiplying by a
factor F, which empirically inflates the time over which
residual clearance is measured, to account for its greater
efficiency compared to that of dialysis, with the value of
F depending on dialysis frequency. A “Combined Kt/V”
is calculated:
Combined eKt=V ¼ eKt=VDialysis þ eKt=VKidney
eKt=VKidney ¼ KruF=Vu
where:
eKt=VDialysis is calculated as above
Vu ¼ volume of distribution of urea mlð Þ;
approximated by 580TW kgð Þ
F ¼ 5500 for thrice weekly schedulesð Þ
With the method above, a Combined eKt/V can be
calculated and the dialysis component adjusted to
achieve a target Combined eKt/V of 1.2.
Converting Kt/V to an equivalent renal clearance
(EKRc)
An alternative method is to convert per-session Kt/V
into an equivalent continuous renal clearance and then
add it to Kru. Casino and Lopez computed kinetic esti-
mates of combined dialysis and kidney urea clearance
(normalized to volume) which they termed “equivalent
renal urea clearance” (EKRc). In the absence of residual
function, an eKt/V target of 1.2 equates to EKRc 13ml/
min. For a thrice weekly schedule EKRc is given by the
formula:
EKRc ml= minð Þ ¼ 1þ 10eKt=Vð Þ
With this method Kru is added to EKRc and the
dialysis component adjusted to achieve a total of 13ml/
min.
Converting both eKt/V and Kru to a weekly dialysis
dose (stdKt/V)
Dialysis schedule and dose can be converted to an
equivalent weekly clearance, “Standard Kt/V” (stdKt/V)
proposed by Gotch, based on kinetic models which
relate urea generation to average weekly pre-dialysis
urea. This allows comparison between schedules: a fre-
quent schedule with stdKt/V = 2.1 is equivalent (in
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terms of small solute clearance) to a thrice-weekly
schedule with eKt/V = 1.2. Residual function can be in-
corporated into stdKt/V (sometimes termed “Total
Standard Kt/V”) by formulas available [259].
Appendix 3
Quantifying convection
Convective clearance of a toxin depends firstly on the
sieving coefficient. Seiving coefficient (SC) is a measure of
the ease with which a solute passes through the
membrane relative to solvent, so this depends largely on
the relative size of the solute molecule and the membrane
pore cross-section. It can be measured during pure ultra-
filtration as the ratio of solute concentration before and
after passing through the membrane. SC takes values be-
tween 0 (the molecule is unable to pass through the mem-
brane) and 1 (the molecule passes just as easily as water).
Secondly, convective clearance depends on the
ultrafiltration rate.
In pure haemofiltration, clearance is achieved entirely
by ultrafiltration. The loss of fluid by ultrafiltration is
replaced by infusion into the blood downstream of the
filter (“post-dilution”). In this case, clearance (K) for any
solute is equal to convective clearance (Kc) and can be
calculated from:
K ¼ Kc ¼ QufSC
where:
Quf ¼ ultrafiltrate flow rate
In haemodiafiltration (HDF), there is a mixture of
diffusion and convection. Diffusion reduces the
concentrations in the ultrafiltrate, reducing Kc. Clearance
in haemodiafiltration can be predicted by the following
equation:
Kc ¼ QufSC Qp−Kdð Þ=Qpð Þ
K ¼ Kcþ Kd
where:
Qp ¼ plasma flow rate
Kd ¼ diffusive clearance
The effect of this is to diminish the convective
component. In post-dilution HDF, convection will al-
ways increase total clearance, but this increase is negli-
gible for small solutes which diffuse easily (such as urea).
For larger molecules (such as beta-2-microglobulin) con-
vection can significantly and usefully increase clearance.
Pre-dilution HDF, in which replacement fluid is given
upstream of the dialyser, is less commonly practiced, and
more complex mathematically. Convection is similarly
reduced by diffusion as above, but in addition both
convection and diffusion are substantially reduced by the
dilutional effect of the replacement fluid. The ultrafiltrate
rate and volume are usually adjusted to account for this.
In publications the convective component of HDF is
quantified as the filtration volume. This means the total
sessional filtration volume in post-dilution HDF, or the
equivalent adjusted volume in pre-dilution HDF.
Appendix 4
Adding phosphate to dialysate
Cleen Ready-To-Use enema comes in a 133ml pack
costing 68p (March 2017). The pack is designed to de-
liver a 118ml dose containing 21.4g of sodium acid
phosphate (sodium dihydrogen phosphate dihydrate
NaH2PO4.2H2O) and 9.4g sodium phosphate (disodium
phosphate dodecahydrate Na2HPO4.12H2O). This gives
a concentration of 1.38mmol/ml phosphate.
The acid concentrate, together with the added enema,
will be diluted according to the proportioning ratio of
the dialysis machine. The volume of enema (VE) that
needs to be added to the canister is given by:
VE mlð Þ ¼ CPO4VACDF=1:38
where:
CPO4 ¼ target dialysate phosphate
0:4mmol=l is commonly usedð Þ
VAC ¼ volume of the acid concentrate e:g:6Lð Þ
DF ¼ dilution factor for the dialysate
eg:35 for machine proportioning at 1 : 34ð Þ
Using these numbers, for example, gives an enema
volume of 61ml to be added to the concentrate. Note
that this formula depends on the formulation of the
enema and is specific to Cleen.
This simple formula ignores the small change in
concentrate volume, as the effect is below the 5%
tolerance allowed for electrolyte concentrations for
haemodialysis and related therapies (ISO 23500 Part 4).
Albalate used the above formula to prepare dialysates
with CPO4 between 0.48 to 1.12mmol/l, reporting good
agreement between measured and target CPO4 using
Gambro and Fresenius machines and a range of acid
concentrates [260].
Sodium content in the phosphate-enriched acid con-
centrate will be reduced (since the enema sodium is
37g/l, compared to around 83g/l for an acid concentrate
that proportions at 1:34, and 107g/l for one that propor-
tions at 1:44). This will lead to a lower dialysate sodium
(by 0.7 to 0.9mmol/l) with volumetric proportioning,
and a higher concentrate pump rate with conductivity
feedback. It is possible that this effect could trigger ma-
chine alarms, requiring machine re-programming.
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Appendix 5
Haemodialysis tasks for shared care
List of dialysis-related tasks that an individual may
choose to learn to perform, as part of shared care:
1. Washing your hands prior to all procedures and
arm (as appropriate) if fistula or graft is used.
2. Recording your weight
3. Recording your blood pressure and pulse
4. Recording your temperature
5. Setting up your dialysis machine
6. Preparing your dressing pack
7. Programming your prescription on the dialysis
machine
8. Putting your needles in or preparing your access line
9. Connecting your lines and commencing dialysis
10. Responding to alerts from your dialysis machine
11. Disconnecting lines and completing your dialysis
12. Applying pressure to needle sites after dialysis or
13. Locking your own access line
14. Administering any of your injections.
Appendix 6
Implementing intradialytic exercise
We suggest the following guidance for implementation
of intradialytic exercise:
a. Exercise should be supervised for greatest
compliance and efficacy by an appropriately trained
individual (e.g. physiotherapist, sport scientist,
cardiac rehabilitation specialist or an assistant
physiotherapist/dietitian/nurse with additional
training from one of the former groups).
b. Exercise should be completed between 30 min and
two hours of the dialysis procedure.
c. Exercise should be completed during all dialysis
sessions (unless contraindicated).
d. Exercise should include both aerobic (e.g.
intradialytic cycling) and resistance (e.g.
TheraBands and/or lifting of ankle weights)
components of lower or upper body, dependent on
access site.
e. Exercise should be preceded by warm up activities
(e.g. exercising for a minimum of five minutes,
gradually increasing intensity until one half of
prescribed training intensity is obtained).
f. Exercise should be completed for at least 30
minutes per hemodialysis session.
g. Exercise should be completed at moderate to
vigorous intensity, ranging from 40-75% of VO2 re-
serve or heart rate reserve (if a graded exercise test
is completed). When a graded exercise test cannot
be completed, and for muscle conditioning exer-
cises, a rating of perceived exertion on the Borg
CR100 scale of “moderate” (20) to “strong heavy
(50)” or on the Borg RPE scale of 12 to 15 can be
used with caution as a method to prescribe exercise
intensity.
h. Volume of exercise should be progressed gradually by
adjusting duration, frequency, and/or intensity until the
desired exercise goal (maintenance) is attained.
i. Exercise should be followed by cool down activities
(e.g. exercising for a minimum of five minutes, starting
at one half of prescribed training intensity and
gradually decreasing intensity until exercise is stopped).
j. Once patients are established exercising during
dialysis, they should be encouraged to complete
additional exercise on non-dialysis days.
k. To enhance adoption and adherence in novice
exercisers, moderate-intensity activity should be
prescribed.
l. To maintain exercise behaviour, behavioural
strategies such as social support, goal setting and
motivational interviewing should be implemented.
We suggest the following patient exclusion criteria/
contraindications to exercise during haemodialysis:
a. Less than three months after initiation of
haemodialysis.
b. Any uncontrolled medical condition including (but not
limited to) infection or fever; recent (within 8 weeks)
myocardial infarction or undiagnosed chest pain.
c. Patient in class D (unstable condition) as per
American Heart Association/American College of
Sports Medicine Joint Position Statement: 1)
unstable ischemia; 2) heart failure that is not
compenstated;3) uncontrolled arrhythmias; 4)
severe and symptomatic aortic stenosis; 5)
hypertrophic cardiomyopathy or cardiomyopathy
from recent myocarditis; 6) severe pulmonary
hypertension; or 7) other conditions that could be
aggravated by exercise (for example, resting systolic
blood pressure >200 mm Hg or resting diastolic
blood pressure >110 mm Hg; active or suspected
myocarditis or pericarditis; suspected or known
dissecting aneurysm; thrombophlebitis and recent
systemic or pulmonary embolus).
d. Symptomatic hyper- or hypotension.
e. Signs and symptoms of deep vein thrombosis.
f. Excessive inter-dialytic weight gain that severely im-
pacts upon indices of fluid retention, e.g. blood
pressure greater than 160/100; heart rate above 100
bpm; breathlessness at rest; or signs of substantial
peripheral oedema.
g. If diabetic, blood glucose above 16.7 mmol/L (300
mg/dL) AND patient is in ketosis (fruity breath,
rapid breathing or shortness of breath, excessive
Ashby et al. BMC Nephrology          (2019) 20:379 Page 29 of 36
thirst, frequent urination, stomach pain, nausea,
vomiting, fatigue or confusion), is dehydrated, or is
feeling unwell.
h. In individuals taking insulin and/or insulin
secretagogues, if hypoglycaemia below 5.5 mmol/L
(100 mg/dL) is observed, and glucose containing
dialysate fails to elevate blood glucose sufficiently,
advise patient to eat or drink approximately 15g
carbohydrate and re-assess blood glucose concen-
tration after 20 min. Repeat until blood glucose ex-
ceeds 5.5 mmol/L.
We suggest the following safety monitoring:
a. Prior to exercise, ask patient how they feel, record
resting blood pressure and heart rate, and if
diabetic, record blood glucose concentration.
b. During exercise, monitor signs and ask patient to
report symptoms of pain, excessive fatigue, altered
consciousness, overheating, cyanosis, anxiety, severe
breathlessness, chest pain, dizziness/light-
headedness.
c. If hypertensive, regularly check blood pressure
during exercise. If values exceed 220/105 mm Hg,
reduce exercise intensity or cease exercising until
blood pressure reduces.
d. Use a rating of perceived exertion scale (Borg
CR100 or Borg RPE scales) and ensure exercise
intensity does not provoke responses greater than
50/strong heavy on the Borg CR100 or 15/hard
(heavy) on the Borg RPE scale
e. Post exercise, monitor blood pressure and heart
rate until resting values are approximately obtained,
observe patient for at least 20 min, and be aware of
possibility of hypotension during remainder of the
dialysis session.
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